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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease associated with
protein misfolding and dysregulated cellular protein quality control mechanisms.
Molecular chaperones, and heat shock proteins (Hsp), are key players in maintaining
cellular protein quality control. DNAJC7 is an understudied cytosolic Hsp40 that works
together with Hsp70 and Hsp90 to regulate proper protein folding or degradation. Of
note, mutations in the gene encoding DNAJC7 were discovered to cause familial ALS.
We asked whether ALS-associated mutations in DNAJC7 compromise its function as a
chaperone, which may cause the toxic accumulation of misfolded proteins. This study
attempts to uncover the functions of DNAJC7 in folding ALS-associated proteins, TDP43 and FUS, using a yeast model, mammalian cultured cells, and human pathological
tissue. Furthermore, we engineered DNAJC7 mutations to be used in future studies. We
propose that DNAJC7 may be involved in the proper folding of TDP-43 and FUS by
allowing these proteins to be passed from Hsp90 to Hsp70 and thus prevent their
misfolding and the ensuing toxicity.

Keywords
Neurodegenerative diseases, Amyotrophic Lateral Sclerosis (ALS), protein quality
control, protein misfolding, molecular chaperones and heat shock proteins, DNAJC7,
Hsp70, Hsp90, TDP-43, FUS
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Summary for Lay Audience
Amyotrophic lateral sclerosis (ALS) is a fatal disease that affects nerve cells in
the brain and spinal cord, eventually leading to complete loss of muscle function.
Unfortunately, there is no cure for ALS, however, scientists have discovered a promising
link between improperly folded proteins within the nerve cell and nerve cell dysfunction.
Proteins are the functional molecules of the cell as they are responsible for our growth,
development, and daily functioning. Thus, when proteins become improperly folded, they
can no-longer preform their function, which can lead to massive problems for the survival
of the cell. Thankfully, this is not a concern in healthy individuals as they have
maintenance mechanisms within the cell that are responsible for either re-folding these
misfolded proteins or destroying them. Conversely, these maintenance mechanisms are
compromised in individuals with ALS, thus, the misfolded proteins accumulate within
the nerve cell, preventing the neuron from functioning properly. Chaperone proteins are
the key players in maintenance mechanisms as they are responsible for refolding
misfolded proteins. In this thesis we explore the role of DNAJC7, a chaperone protein
that becomes abnormally altered in ALS individuals. Little is known about DNAJC7 and
how it functions normally within the nerve cell, let alone how the altered forms of
DNAJC7 may affect its function in ALS individuals. We began our studies in a yeast
model, which enabled us to isolate DNAJC7 and visualize how it functions in a
simplified manner before studying its role in more complex organisms (e.g. mice).
Interestingly, we discovered that DNAJC7 may play a key role in properly folding or
degrading two well-studied proteins, TDP-43 and FUS, that have been shown to misfold
in ALS individuals. Thus, we speculate that the altered DNAJC7 found in ALS
individuals is unable to refold or degrade TDP-43 and FUS, leading to the accumulation
of these proteins in the nerve cell and ultimately nerve cell dysfunction. In this study we
engineered the ALS altered forms of DNAJC7 to be used in future experiments. Overall,
this thesis provides new information about an understudied chaperone protein, DNAJC7,
and engineered ALS-associated altered forms of DNAJC7.
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Chapter 1
1 Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes
the loss of upper motor neurons (neurons that extend from the cortex to the brain stem)
and lower motor neurons (neurons that connect the brain stem or spinal cord to muscle)
(Brown and Al-Chalabi, 2017). As the disease manifests, the affected individual
experiences progressive muscle paralysis and eventually death due to respiratory failure
within 3-5 years following onset (Del Aguila et al., 2003). Currently, there is no cure for
ALS and the molecular mechanisms underpinning this disease remain poorly
characterized. However, the impairment of basic cellular pathways, such as cellular
protein quality control, emerged as major contributing factors to ALS pathogenesis
(Kabashi and Durham, 2006).
In order to function properly, proteins must fold into their proper threedimensional conformation. However, errors in the protein folding process, which can
occur as a result of specific mutations or a stochastic process, can result in loss of protein
function and have disastrous consequences to a cell (Dobson, 2003). For instance,
excessive accumulation of misfolded proteins can trigger cell death through activation of
apoptosis (Lam et al., 2020). Most neurodegenerative diseases, such as Alzheimer’s,
Parkinson’s, Huntington’s and ALS, are associated with protein misfolding (Sami et al.,
2017). Proteins such as TDP-43, FUS, SOD1, and C9orf72, have been shown to misfold
and accumulate in ALS patients leading to neurotoxic effects (Bruijn et al., 1998;
Kwiatkowski et al., 2009; Neumann et al., 2006; Zhang et al., 2014).
In healthy unstressed neurons, protein quality control mechanisms prevent
aberrant misfolded protein accumulation. Molecular chaperones are key players in
protein quality control as they guide other proteins through the processes of folding,
refolding, sequestration, and degradation (Elljis and Hemmingsen, 1989). One of the
most prominent types of molecular chaperones are heat shock proteins (Hsps), which are
conventionally classified according to their molecular weight e.g. Hsp104, 90, 70, 40.
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Each class of Hsp performs a distinct function (Kampinga et al., 2009). My project will
focus specifically on a chaperone within the Hsp40 class, DNAJC7, which is proposed to
aid Hsp70 and Hsp90 in re-folding client proteins.
DNAJC7 mutations were recently identified in ALS patients, but not in
neurotypical individuals (Farhan et al., 2019). These ALS-associated mutations may
compromise the function of DNAJC7, rendering it unable to aid in re-folding misfolded
proteins, which may cause the toxic accumulation of misfolded proteins (i.e., TDP-43,
FUS, SOD1 or C9orf72) and eventually ALS-specific neurodegeneration. My study aims
to understand the role of wild-type DNAJC7 and ALS-associated mutations of DNAJC7.
Of note, there is a lack of information regarding this particular protein, its regular
function, and its importance in cellular protein quality control. Furthermore, it remains
unknown how mutations in DNAJC7 are associated with ALS.

1.1 Protein Folding Within the Cell
In order to function properly, all proteins need to adopt a specific, threedimensional conformation (Chen et al., 2011). Thus, the function of a protein is not only
determined by its primary amino acid sequence, but also by the folding of the polypeptide
chains into its lowest free energy conformation (Chen et al., 2011). Interestingly, the
folding energy landscape of a protein resembles a funnel with several internal peaks,
where the protein must pass through multiple higher-energy folding intermediates
(Leopold et al., 1992) (Figure 1). Misfolding refers to the state of protein in which it is
not folded properly, remains in a higher free energy conformation, and often displays its
hydrophobic amino acid residues on the outside surface (Dobson, 2003).
In the highly crowded intracellular environment, the folding of proteins is also
affected by their interactions with other proteins and the internal conditions of the cell
(Hartl et al., 2011). Thus, proteins can misfold due to specific mutations that alter the
amino acid sequence, exposure to external stress (e.g. heat shock, oxidative stress) or
stochastic unfavourable interactions with other proteins (Chen et al., 2011; Hartl et al.,
2011). Protein misfolding can have detrimental consequences to the cell, as misfolded
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proteins can lose their function, interfere with regular cellular processes, and/or form
multimeric aggregates (Soto, 2003). In some cases, protein misfolding may lead to
mislocalization of a protein, which refers to accumulation of a protein in a cellular
compartment to which the protein is not normally destined. Many diseases, particularly
neurodegenerative disease, are related to aberrant protein folding. One prominent
example of a devastating disease related to protein misfolding and mislocalization is
amyotrophic lateral sclerosis (ALS) (Soto, 2003).

Figure 1. Protein folding energy landscape. Protein folding is a process that begins
with a high entropy, disorganized state and progresses to a low entropy, organized state
with native intramolecular interactions. Thus, proteins fold into their native state by
decreasing their free energy. Adapted from: (Onuchic et al., 1997).

1.2 Protein Quality Control and Molecular Chaperones
Due to the potentially toxic nature of misfolded proteins, organisms possess
multiple complex and highly conserved mechanisms of protein quality control. These
mechanisms act in parallel, and in a coordinated fashion to maintain proteostasis (Chen et
al., 2011). Proteostasis, is the collection of cellular processes involved in the life cycle of
a protein: translation, protein folding, and protein degradation (Balch et al., 2008).
Protein quality control acts to prevent proteins from being misfolded or to re-fold the
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proteins that have already been misfolded. Alternatively, irreparably misfolded proteins
can be sequestered, tagged with ubiquitin, and degraded by the ubiquitin-proteasome
system (UPS) (Chen et al., 2011).
Protein quality control is facilitated by many different molecular chaperones
(Hartl et al., 2011). Besides participating in protein quality control, chaperones also have
a central function in ensuring proper protein trafficking (Hansen and Herrmann, 2019)
and cell signalling (Nollen and Morimoto, 2002). Chaperones are proteins, which guide
folding or re-folding of the client proteins or aid in recognition of misfolded proteins by
the UPS machinery for degradation (Figure 2). Chaperones mainly act by providing a
favourable environment for folding of either the entire protein or a specific region of a
protein, such as a region rich in non-polar residues (Hartl et al., 2011). Many chaperones
function in concert with other chaperones and can form intricate interaction networks,
where a single protein is often passed between several chaperones for proper folding
(Voisine et al., 2010). Chaperones perform most of these functions through cycles of
substrate binding and release, which is often ATP-dependent. Although, most chaperones
are able to bind to substrates independently, many of them rely on co-chaperones to
modulate their efficiency. A co-chaperone is a type of chaperone, which does not directly
fold the protein but instead aids another chaperone in this process. For example, cochaperones may recognize and then present specific client proteins to a chaperone protein
to be folded (Voisine et al., 2010).
Chaperones can be classified either based on their function within the protein
quality control or based on their biochemical mode of action and structure. Among the
structural classes of chaperones, chaperone nomenclature has been based upon their
molecular weight (Kampinga et al., 2009). Some chaperones have been termed Hsps,
since they were first discovered by observing induction of expression of certain genes by
heat shock (Kampinga et al., 2009). It is important to note, however, that not all proteins
named Hsps are induced by heat shock (D’Souza and Brown, 1998). In the context of this
project Hsp90, Hsp70 and Hsp40 classes are particularly important and will be discussed
in greater detail below.
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Figure 2. The role of molecular chaperones in protein quality control. Nascent
polypeptides emerge from the ribosome and takes on a folding intermediate conformation
which vaguely resembles the native protein. Misfolded proteins can be either refolded,
sequestered, or targeted for degradation. Each of these processes are facilitated by
chaperone proteins.

1.2.1

Hsp70
Hsp70s are among the most ubiquitous classes of chaperone proteins and are

highly conserved amongst all living organisms. Hsp70 chaperone proteins are important
for controlling all aspects of cellular protein quality control, from proper protein folding,
refolding misfolded proteins, and controlling target proteins for degradation (Kampinga
and Craig, 2010). This is all achieved through cycles of ATP binding, ATP hydrolysis,
and ADP release, mediated by co-chaperones (Rosenzweig et al., 2019).
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Hsp70 is composed of two structural distinct main domains (Figure 3A). The Nterminal nucleotide binding domain (NBD) is typically 40kDa and is responsible for
binding and hydrolyzing ATP (Rosenzweig et al., 2019). The C-terminal substrate
binding domain (SBD) is typically 25kDa and recognizes exposed hydrophobic regions
in early stages of client protein folding. The SBD contains two subdomains, a 𝛽-sheet
domain for substrate binding (SBD-𝛽) and an 𝛼-helical domain called the “lid” (SBD-𝛼).
The two domains, NBD and SBD, are tethered together by a small flexible linker
(Rosenzweig et al., 2019). In the ADP-bound state with the peptide associated, NBD and
SBD are tethered together, and the “lid” of SBD is covering the substrate binding site. In
the ATP-bound state, the 𝛽-sheet domain and “lid” of SBD bind to different regions on
the NBD leaving the substrate-binding domain available for fast and low-affinity
substrate binding (Rosenzweig et al., 2019). The Hsp70 chaperone cycle is relatively
slow due to the low ATPase activity. Thus, Hsp70 relies on co-chaperone proteins, such
as J-proteins (Hsp40), that recruit client proteins to Hsp70 and increase the ATPase
activity of Hsp70 (Clerico et al., 2019) (Figure 3B).
The yeast, S. cerevisiae, contains many different types of Hsp70s, which are
typically divided into three groups: cytosolic, mitochondrial, and ER-associated. The
cytosolic proteins include Ssa1-4, Ssb1/2 and Ssz1, the mitochondrial proteins include
the Ssc1, Ssq1, and Ecm10, and finally the ER-associated proteins include Kar2
(Boorstein et al., 1994). This study focuses specially on the cytosolic Hsp70 proteins,
which can be broken down into two sub-categories: canonical (Ssa1-4) and ribosome
associated (Ssb1/2 and Ssz1) Hsp70 proteins, which have very distinct non-overlapping
functions. The canonical Ssa family are primarily responsible for folding proteins
including misfolded proteins in response to stress and regulation of the heat shock
response itself. Additionally, Ssa proteins are involved in recognizing target proteins for
ubiquitination and degradation. Ssa proteins are activated by J-proteins (Hsp40s) and
Nucleotide Exchange Factors (NEF) (Boorstein et al., 1994). NEF proteins include
Sse1/2. The ribosome-associated proteins Ssb1/2 are recruited to the ribosome through
their interaction with the Ribosome-Associated-Complex (RAC), which includes the Jprotein Zuo1p (Hsp40) and the Hsp70 Ssz1(Boorstein et al., 1994). Yeast RAC acts as a
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co-chaperone complex to aid in stimulating the ATPase activity of Ssb1/2 proteins.
However, the role of Ssz1 in the RAC remains widely unknown (Zhang et al., 2017). The
major proteins in the Hsp70 system listed above are conserved in all metazoans.
However, humans possess additional paralogs of some cytosolic Hsp70s.

A

B

Figure 3. Structure of Hsp70 and its interaction with Hsp40 during client protein
folding. A Structural schematic of Hsp70 consisting of two major domains and a flexible
linker region. The two domains include the nucleotide binding domain (NBD, purple) and
the substrate binding domain (SBD, red). The SBD also includes a PTIEEVD region on
the C-terminus. B 1. Hsp40 recognizes the client protein and binds to it utilizing its
peptide-binding domain. 2. Hsp40 presents the client protein to Hsp70 for proper folding.
The J-domain of Hsp40 is recognized by the nucleotide binding domain of Hsp70 and
ATP is hydrolyzed to ADP which leads to the closed conformation of Hsp70. Hsp40
leaves the complex and a phosphate molecule is released. 3. The client protein is closed
within Hsp70 and the constraint forces the client protein to fold properly. 4. Nucleotide
exchange factor (NEF), which has a higher affinity for Hsp70(ADP) than Hsp70(ATP),
binds to Hsp70. ADP dissociates and ATP binds to Hsp70 causing Hsp70 to open its
conformation. This causes the native folded client protein to leave the structure due to its
low affinity for Hsp70(ATP).
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1.2.2

Hsp40
Hsp40, also known as DNAJ or J-proteins, are the most diverse group of

chaperone proteins. There are 22 DNAJs found in S. cerevisiae and 50 in H. sapiens (Li
et al., 2009). The defining feature of all Hsp40 proteins is the highly conserved J-domain
region which is approximately 70 amino acids long (Penke et al., 2018)(Kampinga and
Craig, 2010). The J-domain contains the histidine-proline-aspartic acid (HPD) motif
which is required for stimulating ATP hydrolysis in Hsp70 (Greene et al., 1998). Hsp40
possess J-domain dependent and independent functions. The J-domain dependent
function of Hsp40 is to participate in the Hsp70 cycle by first binding the un-folded client
protein, presenting it to Hsp70, and facilitating Hsp70 ATPase activity (Zarouchlioti et
al., 2018) (Figure 3B). The J-domain independent functions are highly specific to each
individual J-protein and can range from participating in cellular iron homeostasis to
medicating protein degradation (Zarouchlioti et al., 2018). Due to the diversity of Hsp40
chaperone family they are thought to act as specific adaptors for a generalist function of
Hsp70 and possibly Hsp90s.
The Hsp40 family can be divided into three classes based on the domains they
possess (Class A, B, and C) (Figure 4) (Li et al., 2009). Class A (DNAJA) have a Nterminal canonical J-domain, glycine/phenylalanine (G/F)-rich region, a zinc-finger motif
and a C-terminal client binding domain (CBD) (Li et al., 2009). Class B (DNAJB)
possess a N-terminal J-domain, and G/F-rich region. Class C (DNAJC) only have the
canonical J-domain which can be located anywhere in the structure of the protein (Li et
al., 2009). DNAJC proteins are the largest and most diverse class of Hsp40s, indicating
more specialized functions in comparison to their J-protein counterparts.
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Figure 4. Structure of the three classes of Hsp40’s. All three classes possess a
conserved, 70-amino acid long J-domain. Class A also contains a glycine/phenylalanine
region, zinc-finger domain and client binding domain. Class B only includes a
glycine/phenylalanine region in addition to its J-domain. Class C possesses only a Jdomain.

1.2.2.1

DNAJC7: A Unique Type of Hsp40

DNAJC7, also known as TOPLESS-related protein 2 (Tpr2), is a unique class C,
Hsp40 chaperone protein that is 56 kDa, 494 amino acids long and is ubiquitously
expressed within the cytosol of the cell in human tissue and cell culture, under favourable
growth conditions (Figure 5) (Uniprot: Q99615). Apart from the canonical J-domain
located at the C-terminus, DNAJC7 also uniquely possesses two tetratricopeptide repeat
(TPR) domains which are composed of three TPR structural motifs each (Brychzy et al.,
2003). The TPR domain allows proteins, particularly co-chaperones, to recognize Hsp90
(Chadli et al., 2008). Proteins containing both a J-domain and TPR domain are rare
amongst eukaryotes and non-existing in S. cerevisiae (Qiu et al., 2006). Thus, DNAJC7 is
an unconventional Hsp40 protein. The J-domain of DNAJC7 shows significant homology
to other human Hsp40s, the functional HPD motif is conserved. This indicates that
DNAJC7 can stimulate the ATPase activity of Hsp70, which is required for the ability of
Hsp70 to refold client proteins (Brychzy et al., 2003). In contrast, the specific role of the
TPR domains in DNAJC7 is less understood. It is believed that the TPR domains in
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DNAJC7 facilitate its interaction with Hsp90, another chaperone class involved in refolding proteins (Brychzy et al., 2003).
DNAJC7 can utilize its J-domain and function as a typical Hsp40 chaperone
protein, independent of its TPR domains. For example, DNAJC7 can substitute for the
function of DNAJA1/B1 in progesterone receptor and CHK1 kinase folding via the
Hsp70/Hsp90 pathway (Cintrón Moffatt et al., 2008). However, DNAJC7 can also
perform functions dependent on its TPR domains. For example, TPR domains of
DNAJC7 disrupt the interaction of Hsp90 with its client, while the J-domain facilitates
the Hsp70 ATPase activity. Thus, DNAJC7 may act as a bridge between Hsp70 and
Hsp90 and work to pass the substrate from Hsp90 back to Hsp70 after the initial folding
cycle (Brychzy et al., 2003). This is the reversed pathway of Sti1, an Hsp90 co-chaperone
protein, which allows the substrate to be passed from Hsp70 to Hsp90. This is further
confirmed in the literature as DNAJC7 cannot substitute for the function of Sti1 (Cintrón
Moffatt et al., 2008).

Figure 5. Domain structure of wild-type DNAJC7. Consists of two tetratricopeptide
repeat domains, one at the N-terminal and another roughly in the middle of the protein.
The J-domain is located near the C-terminus.

1.2.2.2

DNAJC7 in ALS

DNAJC7 has been implicated as a novel gene in ALS. DNAJC7 was found to
have four missense mutations, four nonsense truncations , and one frame-shift mutation
in ALS patients, but the gene is unaffected in neurologically normal individuals (Table 1)
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(Farhan et al., 2019). These ALS-associated mutations may cause a loss of function of
DNAJC7, rendering it unable to assist in re-folding misfolded proteins, which may cause
the toxic accumulation of ALS-associated misfolded proteins (ie., TDP-43, FUS, SOD1
or C9orf72).

Table 1: DNAJC7 mutations associated with ALS
Variant type

cDNA change

Protein change

ALS cases
(n=5095)

Nonsense

c.97G>T

p.E33X

1

Control
cases
(n=28,910)
0

Nonsense

c.358C>T

p.Q120X

1

0

Nonsense

c.466C>T

p.R156X

2

0

Nonsense

c.646C>T

p.R216X

2

0

Frameshift

c.488delT

p.F163fs

1

0

Missense

c.22G>C

p.D8H

1

0

Missense

c.235C>T

p.R79W

0

1

Missense

c.631G>A

p.D211N

1

0

Missense

c.1234C>T

p.R412W

1

0

Missense

c.1273G>A

p.E425K

2

0

Adapted from: (Farhan et al., 2019)

1.2.3

Hsp90
Hsp90 is a highly conserved cytosolic molecular chaperone that is a key regulator

of proteostasis under both physiological and stress conditions. It is responsible for the
folding activation of over 200 client proteins such as kinases, transcription factors, steroid
hormone receptors, E3 ubiquitin ligases, among others (Schopf et al., 2017). The
structure of Hsp90 consists of three domains (Figure 6A). The N-terminal domain is
responsible for ATP-binding and hydrolysis, the middle domain is important for client
and co-chaperone binding, and the C-terminal domain is required for dimerization of the
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protein. In eukaryotes, at the very end of the C-terminal domain of the protein is a
tetratricopeptide repeat (TPR) motif recognition site, MEEVD, responsible for binding to
co-chaperones with tetratricopeptide repeats (TPR) (Taipale et al., 2010). Hsp90
undergoes essential conformational changes in response to ATP binding, hydrolysis, and
ADP release. In the absence of ATP the Hsp90 dimer acquires an open ‘V’-shaped
structure such that the C-terminal domains are interacting (Figure 6B). Once the Nterminal domain of Hsp90 binds to ATP, the Hsp90 dimer adopts a “closed” confirmation
with the two N-terminal domains interacting, this maximizes the ability of client proteins
to bind (Figure 6B). Additional conformational changes occur upon ATP hydrolysis
resulting in an ADP-bound confirmation. Once ADP is released the Hsp90 dimer reverts
back to its original “open” confirmation (Li et al., 2012). Although the function of Hsp90
is largely dependent on ATPase activity, the ATP turnover rate is fairly slow. Thus, the
Hsp90 chaperone system relies on co-chaperone proteins to inhibit or stimulate the
ATPase cycle (Hoter et al., 2018).
There are two cytosolic Hsp90 isoforms in Saccharomyces cerevisiae, Hsp82
and Hsc82; together they are essential for cell viability under both optimal and stress
conditions (Girstmair et al., 2019). Hsp82 is expressed normally at low levels and upregulated ~20-fold under heat stress or other stress conditions. Hsc82 is constitutively
expressed at higher basal levels and is only slightly induced by heat shock. Hsp82 and
Hsc82 are ~97% identical in sequence homology (Girstmair et al., 2019). Under normal
temperature conditions only one isoform needs to be present for cell viability. However,
at higher temperatures and/or stress conditions both isoforms are necessary for cell
viability (Borkovich et al., 1989).
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Figure 6. Structure of Hsp90 and its interaction with client proteins. A Structural
schematic of yeast heat inducible Hsp90. Hsp90 consists of 3 domains the N-terminus,
central domain, and C-terminus. The C-terminus also contains a tetratricopeptide repeat
recognition site, MEEVD. B ATP-dependant Hsp90 client-binding mechanism. The
client protein binds to the central domain of Hsp90, ATP then binds to the N-terminal of
Hsp90 which induces Hsp90 to close its conformation around the client protein.

1.2.3.1 Hsp90 Co-chaperones
Hsp90 has a highly diverse set of client proteins and thus relies heavily on a
variety of co-chaperones to regulate its activity. Co-chaperones are able to inhibit or
stimulate the ATPase activity of Hsp90 and facilitate the folding or activation of its client
protein (Li et al., 2012). This study focuses specifically on the Hsp90 co-chaperones
Cdc37, and Sti1.
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1.2.3.1.1 Cdc37
Cell division cycle 37 (Cdc37), also known as p50, is a co-chaperone that binds
protein kinases in order to stabilize or stimulate their activity in different stages of cell
cycle progression (Figure 7A). Kinases are important for the regulation of cell cycle
progression, signal transduction, and transcription regulation (Gray et al., 2008). Cdc37
homologues are conserved from yeast to humans. The N-terminal domain of Cdc37 binds
to the protein kinases. The central-domain of Cdc37 binds to N-terminal domain of
Hsp90, inhibiting the ATPase activity of Hsp90, this may prolong the interaction between
the client protein and Hsp90 facilitating more effective chaperoning activity (Figure 7B)
(Silverstein et al., 1998; Verba and Agard, 2017).
Cdc37 can also function independently from Hsp90 in folding kinase clients.
Cdc37 has been shown to compensate for decreased Hsp90 function in vivo (Lee et al.,
2002; MacLean and Picard, 2003). However, Cdc37 more optimally cooperates with
Hsp90 in folding of kinase proteins (MacLean and Picard, 2003). The Hsp90-Cdc37
complex also appears to play a role in protein quality control through the upstream
activation of autophagy (Joo et al., 2011). Autophagy is a major protein degradation
pathway involved in the clearance of aggregates. Abnormalities in autophagy has been
linked to various neurogenerative diseases, including ALS (Nixon, 2013). Thus, the
Hsp90-Cdc37 complex may play a major role in clearing the misfolded proteins through
the autophagy pathway in neurogenerative diseases (Jinwal et al., 2012).
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Figure 7. Structure of Hsp90 co-chaperone, Cdc37, and its interaction with Hsp90.
A Structural schematic of Cdc37 consisting of 3 domains, N-terminus, central domain,
and C-terminus. B The central domain of Cdc37 binds to the N-terminal domain of
Hsp90 inhibiting the ATPase activity of Hsp90 and prolonging the interaction of a client
protein with Hsp90.

1.2.3.1.2 Sti1
Stress-inducible phosphoprotein 1 (Sti1), also known as Hsp70/Hsp90 Organizing
Protein (Hop) in animals, is an intracellular co-chaperone protein that mediates the
transfer of client proteins from Hsp70 to Hsp90 (Li et al., 2012). Yeast cells with the Sti1
encoded gene deleted show no growth defect under optimal conditions, however under
limiting conditions the cells grow poorly, indicating that Sti1 is not essential for yeast cell
survival under normal conditions (Chang et al., 1997). In contrast, Sti1 gene knockout in
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mice is embryonically lethal, indicating that Sti1 is essential for mammalian development
or cell function (Beraldo et al., 2013).
Sti1 consists of nine tetratricopeptide repeat (TPR) motifs, which are clustered
within three TPR domains (Figure 8A). Sti1 binds simultaneously to Hsp70 and Hsp90,
as a scaffold protein, through the use of different TPR domains (Schmid et al., 2012).
Sti1 binds to the C-terminal TPR recognition site, MEEVD, on Hsp90 and binds to the
PTIEEVD polypeptide chain of Hsp70 simultaneously using another TPR motif (Schmid
et al., 2012). While binding to the C-terminal of Hsp90, Sti1 also physically interacts
with the N-terminal of Hsp90, this inhibits the ATPase activity and stabilizes the open
conformation of Hsp90. Next, Sti1 unloads the client protein from Hsp70 into the open
conformation of Hsp90 (Li et al., 2012). After the client protein binds to the middle
domain of Hsp90, another Hsp90 Co-chaperone protein (Aha1) outcompetes Sti1 in order
to increase the ATPase activity and stimulate a closed conformational state of Hsp90.
Finally, upon ATP hydrolysis, the client proteins and co-chaperones dissociate from
Hsp90 (Li et al., 2012) (Figure 8B).
Sti1 is predominately a cytosolic chaperone protein, however it can be
translocated into the nucleus upon heat shock through the use of its nuclear-localization
sequence (NLS)(Daniel et al., 2008). The NLS in Sti1 is located within the Hsp90binding domain (TPR2A) (Figure 8A) (Longshaw et al., 2004). Amino acid substitution
within the major arm of the NLS prevented Sti1-Hsp90 interaction (Daniel et al., 2008).
Dysregulation of the Hsp90-Hsp70 chaperone complex system is present in both
ageing brains and neurodegenerative diseases (Lackie et al., 2017). Furthermore, the
proper function of the Hsp90-Hsp70 complex is highly reliant on regulation by Sti1, thus,
it is important to study Sti1 due to its various roles in protein misfolding and its link to
chaperone systems involved in neurodegenerative diseases (Li et al., 2012).
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Figure 8. Structure of Sti1 and its bridging interaction with Hsp70 and Hsp90. A
Structural schematic of Sti1 consisting of three tetratricopeptide repeat (TPR) domains,
nine TPR motifs and a nuclear localization sequence (NLS). B 1. Sti1 uses its TPR1
domain to bind to the C-terminal MEEVD region of Hsp90 while simultaneously making
physical contact with the N-terminal of Hsp90, inhibiting Hsp90 ATPase activity. 2. Sti1
utilizes a different TPR domain to bind to the C-terminal (PTIEEVD) of Hsp70. Sti1
unloads the client protein from Hsp70 into the open conformation of Hsp90. 3. Aha1
outcompetes Sti1 to increase the ATPase activity of Hsp90 and lead to a closed
conformation around the client protein. 4. Upon ATP hydrolysis the folded client protein
is released, and the co-chaperones disassociate from Hsp90.

1.3 Neurodegenerative Diseases
Misfolding, aggregation, and accumulation of proteins is a hallmark of many
neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia
(FTD). In most cases protein aggregation and misfolding are caused by stochastic
processes and manifest in an age-dependent manner (Ross and Poirier, 2004). For the
purposes of this study we focus on ALS.
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1.3.1 Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a
progressive and fatal neurodegenerative disease. It is characterized by the progressive
loss of muscle function, leading to fatal paralysis of the respiratory system 3-5 years
following disease onset (Figure 9). Onset is typically age-dependent with the majority of
patients becoming diagnosed at ~60 years of age (Marin et al., 2018). The lifetime risk of
developing ALS is more prominent in males, the male to female ratio is 1.6 to 1, this
statistic is exaggerated for those who have served in the military (Tiryaki and Horak,
2014). There is currently no cure for ALS, however, to date there are two known drug
treatments, Riluzole and Radicava, both of which are only minimally effective. In 1995,
Riluzole was approved in USA for the treatment of ALS. Riluzole has been proven to
delay the onset of ventilator-dependence and increase the survival of patients by 2-3
months (Jaiswal, 2019). In 2017, Radicava/Edaravone was approved and is known to be
an antioxidant which may work by minimizing the oxidative stress in neurons. Oxidative
stress has been hypothesized to be a major cause of neuronal cell death in ALS patients.
In some trials Radicava has been shown to improve the muscle function of patients,
however, its impact on life expectancy is unknown (Jaiswal, 2019). The onset of ALS
presents itself uniquely in each patient. For example, some patients present with spinalonset (weakness of limbs), but others present with bulbar-onset (difficulty speaking,
breathing, swallowing) (Marin et al., 2018). The disease is also classified further based
on its mode of heritability, sporadic ALS (sALS) and familial ALS (fALS). sALS
accounts for 90% of all ALS cases, whereas fALS accounts for 10% (Ross and Poirier,
2004).
In 1993, the first cause of fALS was identified as a mutation in the copper-zinc
superoxide dismutase-1 (SOD1) (Rosen et al., 1993). SOD1 mutations are responsible for
20% of all fALS cases and only 1% of all sALS cases (Lagier-Tourenne and Cleveland,
2009). In the last 27 years a number of new ALS causing genes have been discovered.
For example, TDP-43 inclusion bodies were discovered in the brains of ALS patients in
2006, thus becoming the second known ALS protein. FUS was discovered in 2009,
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followed by C9ORF72 in 2011, NEK-1 in 2016, and most recently DNAJC7 in 2018
(Farhan et al., 2019; Hartl, 2017).

Figure 9. Amyotrophic Lateral Sclerosis (ALS) progressive loss of muscle function.
1. Healthy motor neuron signalling muscle to contract. 2. Diseased ALS motor neuron
sending depleted signals to the muscle ultimately leading to a weakened muscle. Adapted
from: http://www.arisla.org/?page_id=1654&lang=en

1.3.1.1

Amyotrophic Lateral Sclerosis (ALS)-Associated

Misfolded Proteins
On a pathological level, ALS is characterized by protein aggregates or inclusions
in motor neurons containing specific ALS-associated proteins such as, TDP-43 and FUS
(Kim et al., 2010). TDP-43 and FUS, which are related to this study, will be discussed
below.

1.3.1.1.1 TDP-43: Transactive Response DNA Binding Protein 43
Transactive Response (TAR) DNA-Binding Protein 43 (TDP-43), also known as
ALS10, is a 43 kDa and 414 amino acid long DNA/RNA binding protein. TDP-43 is
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ubiquitously expressed in the nucleus but also shuttles to the cytoplasm for some of its
functions (Cohen et al., 2011). TDP-43 consists of two RNA recognition motifs (RRM)
that are responsible for RNA binding, a nuclear localization sequence (NLS), a nuclear
export sequence (NES) located in the second RRM (RRM2), and a glycine-rich prion-like
domain located at the C-terminus that mediates protein-protein interactions (Figure 10)
(Cohen et al., 2011).
In the nucleus, TDP-43 regulates RNA splicing and processing of microRNA, and
thus influences diverse cellular processes (Tollervey et al., 2011). In the cytoplasm
(~30% of TDP-43 protein) TDP-43 is important for the transport of granules containing
RNA between the body and the dendrites of the neuron cell and plays an important role in
neuronal plasticity (Chu et al., 2019). Furthermore, TDP-43 is also important for playing
a role in cytoplasmic stress granule formation, indicating that TDP-43 is important under
cellular stress conditions (Colombrita et al., 2009).
In 2006, TDP-43 proteinopathy was identified as a key component in ALS and
frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U). In TDP43 proteinopathy TDP-43 mislocalizes to the cytoplasm following the formation of
inclusions or aggregates in the cytoplasm of the neuron (Neumann et al., 2006) (Figure
11). The disease-associated form of TDP-43 is often ubiquitinated, hyperphosphorylated,
or cleaved into smaller fragments (25 and 35 kDa) containing the C-terminus (Neumann
et al., 2006; Zhang et al., 2009). TDP-43 proteinopathy is not unique to ALS and FTLD
but is also present in other neurodegenerative diseases such as, Alzheimer’s disease
(AD), Parkinson’s disease (PD), and Huntington disease (HD) (Higashi et al., 2007;
Schwab et al., 2008).

Numerous mutations in the TDP-43 gene have been identified to be associated
with ALS and FTLD. These TDP-43 mutations have been shown to mislocalize,
aggregate, and modify binding interactions with other proteins (Prasad et al., 2019). The
majority of TDP-43 mutations in both sporadic and familial ALS are located in the Cterminal glycerine-rich region with the exception of two mutations located in the Nterminal and the RRM1(Pesiridis et al., 2009). It has been reported that TDP-43

21
fragments containing the N-terminal domain and RRM1 are soluble and do not aggregate,
while fragments containing RRM2 and the C-terminal region, which contains its prionlike domain, aggregate with similar efficiency as full-length TDP-43 (Igaz et al., 2009;
Yang et al., 2010). This contributes to the theory that the C-terminal domain is essential
for aggregation of TDP-43.
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Figure 10. Schematic representation of the domain structure of ALS-associated
protein, TDP-43. Including two RNA recognition motifs (RRM), nuclear localization
sequence (NLS), nuclear export sequence (NES), and a glycine rich, prion like domain.

Figure 11. TDP-43 proteinopathy in neurons cells. In healthy neurons TDP-43 is
diffused within the nucleus. In neurons with TDP-43 proteinopathy, TDP-43 aggregates
and mislocalizes in the cytosol. This causes a toxic loss of function in the nucleus and a
toxic gain of function in the cytoplasm.
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1.3.1.1.2 FUS: Fused in Sarcoma
Fused in Sarcoma (FUS), also known as hnRNP P2 or ALS6, is a 75 kDa and 526
amino acid long DNA/RNA binding protein (Mejzini et al., 2019) FUS is located in the
nucleus where it is involved in transcription, DNA repair, and damage response, as well
as RNA biogenesis (Patel et al., 2015). FUS consists of an N-terminal prion-like domain
involved in protein-protein interactions, and a C-terminal domain important for RNAbinding which includes an RNA-recognition motif (RRM) and a zinc-finger (ZnF)
domain, that are interspersed between three regions rich in RGG repeats. The C-terminal
domain also includes a Proline-Tyrosine nuclear localization sequence (PY-NLS) (Figure
12) (Mejzini et al., 2019).
There are over 50 mutations in FUS associated with ALS and the majority of
these mutations are located in the PY-NLS region of the C-terminal domain (An et al.,
2019). This would affect the nuclear import of FUS leading to a toxic accumulation of
FUS inclusions in the cytoplasm (Ito and Suzuki, 2011). FUS mutations have also been
shown to affect RNA metabolic process, splicing, transcription, and mRNA transport
(Kamelgarn et al., 2018).
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Figure 12. Schematic representation of the domain structure of ALS-associated
protein, FUS. Including a prion like domain (PrLD), three RGG repeats, nuclear export
sequence (NES), Zinc finger domain (ZnF), and a proline-tyrosine nuclear localization
sequence (PY-NLS).
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1.3.1.1.3 Physical Interaction Between TDP-43, FUS, and DNAJC7
Interestingly, FUS has been shown to physically interact with both DNAJC7 and
TDP-43 in a high-throughput proteomics study by anti-bait coimmunoprecipitation (Li et
al., 2015) (Figure 13). This potential interaction between FUS and DNAJC7 has not yet
been characterized in vivo or in vitro. Even though only a fraction of wild-type FUS (less
than 1%) is known to interact with wild-type TDP-43, this interaction becomes stronger
with ALS-associated mutations in TDP-43 (Ling et al., 2010). The proteomics studies
referenced in the STRING database did not detect a direct interaction between DNAJC7
and TDP-43, however TDP-43 is known to interact with Hsp70 (Kitamura et al., 2018).
Therefore, the interactions between DNAJC7 and FUS or TDP-43 have yet to be
characterized.

Figure 13. The interaction network of FUS. FUS and DNAJC7 have a strong, direct
physical interaction. FUS and TARDBP (TDP-43) also have a direct physical interaction.
The thickness of the line between the nodes indicates the confidence level of the
interaction. This interaction network was obtained from the STRING consortium data
base. FUS was chosen as the network central node and all interactions above the high
confidence level (0.7) are shown.
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1.4 Yeast as a Model Organism
Saccharomyces cerevisiae, commonly known as baker’s yeast or budding yeast, is
a eukaryotic single-celled organism that is frequently used as a model to study
mechanisms underlying protein misfolding in living cells (Tenreiro and Outeiro, 2010). S.
cerevisiae is a useful model organism mainly because of its genetic tools, rapid growth,
ability to perform high-throughput studies, and the availability of a well-established
genome database. In fact, yeast was the first eukaryotic organism to have its genome
sequenced and there are plenty of yeast deletion and overexpression libraries available for
investigating genetic interactions (Botstein and Fink, 2011).

Yeast cells are also able to adjust their metabolism and cell division rate based on
the carbon source they are provided (Zaman et al., 2008). For example, in media
containing fermentable carbon sources, such as glucose or galactose, yeast cells divide
rapidly and rely on glycolysis and anerobic fermentation as a main source of energy.
However, in media containing non-fermentable carbon sources, such as glycerol, yeast
cells divide significantly slower and rely on oxidative phosphorylation carried out by the
mitochondria as their major source of ATP energy (Broach, 2012). Thus, yeast can serve
as a proxy for various cell types, most importantly neuron cells which mostly utilize
oxidative phosphorylation for ATP production (Agostini et al., 2016).

Furthermore, yeast and humans share conserved cellular processes and twentythree percent gene homolog (Botstein and Fink, 2011; Liu et al., 2017b). Thus, many of
the mechanisms and roles of molecular chaperone proteins are maintained in all
eukaryotes. The molecular chaperones we investigate in this study, Hsp40, Hsp70 and
Hsp90 and their associated co-chaperones, are amongst those that have been well studied
in the yeast model and are overall highly conserved between yeast and humans (Verghese
et al., 2012).

The factors listed above enable yeast to be a suitable model organism for studying
protein misfolding in human diseases, which is a hallmark of neurodegenerative diseases.
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The yeast model has been used to study α-synuclein (α-syn) and Parkin (PARK2) in
Parkinson’s Disease (PD), the Huntington (Htt) polyQ expansion in Huntington’s Disease
(HD), Aβ in Alzheimer’s disease (AD), as well as TDP-43, FUS, SOD1 and many other
proteins in ALS (Di Gregorio and Duennwald, 2018; Hofer et al., 2018; Menezes et al.,
2015; Treusch et al., 2011). In this study we utilize two well-established yeast models,
TDP-43 and FUS, to explore their relation to the molecular chaperone protein, DNAJC7.
Both the TDP-43 and FUS yeast model recapitulate the mislocalization, aggregation, and
some potential mechanisms of toxicity in humans diagnosed with ALS (Hayden et al.,
2020; Johnson et al., 2008; Ju et al., 2011; Liu et al., 2017).

1.5 Rationale, Hypothesis, Objectives, and Significance
1.5.1

Rationale

There is currently no cure for ALS and the molecular mechanisms of this disease remain
widely unknown. A major hallmark of neurodegenerative diseases, such as ALS, is the
accumulation of misfolded proteins which ultimately lead to neuronal cell death.
Chaperone proteins are fundamental aspects of protein quality control in the cell that help
reduce the toxic accumulation of misfolded proteins. DNAJC7 is an understudied Hsp40
chaperone protein that was recently discovered to be highly mutated in ALS individuals.
These ALS-associated mutations may compromise the function of DNAJC7, rendering it
unable to aid in re-folding misfolded proteins, which may cause the toxic accumulation of
ALS-associated misfolded proteins (ie. TDP-43 or FUS). Potential causative relevance of
DNAJC7 mutations in ALS and the lack of extensive information about the cellular
function and importance of DNAJC7 in protein quality control provide a strong rationale
to study wild-type DNAJC7 and its ALS-associated mutations in different experimental
models.
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1.5.2

Hypothesis and Objectives

We hypothesize that compromised DNAJC7 function contributes to the toxic
accumulation of misfolded proteins observed across multiple ALS models. In order to
test our hypothesis, we pursue three objectives:
1) Determine the function and localization of wild-type DNAJC7
2) Explore how ALS-associated DNAJC7 mutations and truncations modulate its
function in cellular protein quality control
3) Examine how DNAJC7 modulates the misfolding of ALS-associated proteins
TDP-43 and FUS
The objectives and experimental approaches we employ in this study are summarized in
Figure 14.

Figure 14. Graphic summary of this study.
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1.5.3

Significance

There is currently little information regarding the localization and mechanistic role of
wild-type DNAJC7, yet this particular chaperone protein was discovered to be highly
mutated in ALS individuals. Understanding the wild-type function of DNAJC7 is critical
to uncovering how its mutated counterparts contribute to an ALS diagnosis. Therefore,
studying wild-type and mutated versions of DNAJC7 and its interactions with ALSassociated misfolded substrates, TDP-43 and FUS will provide insight into a potential
new therapeutic solution for ALS.
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Chapter 2
2 Materials and Methods
2.1 Materials
2.1.1 Yeast Strains
Yeast strain BY 4741 (MAT α his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) (Cashikar et al.,
2005)and W303 (MATa/MATα* {leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15}
[phi+]) (Thomas and Rothstein, 1989) were used in this study. Yeast deletion strains
were obtained from the Saccharomyces Genome Deletion Library distributed by Horizon
Discovery Inc. The Genome Deletion Library is a collection of single yeast gene deletion
strains, which correspond to every non-essential gene deleted in one yeast strain. The
yeast Decreased Abundance by mRNA Perturbation (DaMP) library distributed by
Horizon Discovery Inc was used to obtain DAmP Cdc37(Breslow et al., 2008).
Table 2: Hsp70 deletion strains used in this study
Yeast strain

Δssa1

*Function of Deleted Gene

Hsp70 involved in protein folding and NLS-nuclear
transport and required for ubiquitin-dependent
degradation of short-lived proteins

Δssa2

Hsp70 involved in protein folding, vacuolar import of
proteins required for ubiquitin-dependent degradation of
short-lived proteins.

Δssa3

Hsp70 ATPase involved in protein folding and the
response to stress; plays a role in SRP-dependent co-
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translational protein-membrane targeting and
translocation

Δssa4

Plays a role in SRP-dependent co-translational proteinmembrane targeting and translocation

Functions with J-protein partner Zuo1p and may be
Δssb1

involved in folding of newly-made polypeptide chains.
Ribosome-associated

Δssb2

Functions with J-protein partner Zuo1p and may be
involved in the folding of newly-synthesized polypeptide
chains. Ribosome-associated

Δsse1

Serves as nucleotide exchange factor to load ATP onto
the SSA class of cytosolic Hsp70s. Plays a role in prion
propagation and determining prion variants as well as
binds unfolded proteins

Δsse2

Serves as nucleotide exchange factor to load ATP onto
the SSA class of cytosolic Hsp70s. May be involved in
protein folding.

Δssz1

Interacts with Zuo1 (DNAJ homolog) to form a
ribosome-associated complex

All deletion strains were conducted in BY 4741
*Function derived from Saccharomyces Genome Database (SGD)
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Table 3: Hsp90 deletion strains used in this study
Yeast Strain

ΔHsp82

*Function of Deleted Gene

Stress-induced folding of proteins. Hsf1 negative
regulation.

ΔHsc82

Constitutively aids in folding difficult to fold proteins.

*Function derived from Saccharomyces Genome Database (SGD)

Table 4: Hsp90 co-chaperone strains used in this study
Yeast Strain

*Function of Attenuated Gene

DAmP Cdc37

Essential Hsp90 co-chaperone. Presents client proteins to
Hsp90.

ΔSti1

Hsp co-chaperone. Interacts with the ssa group of the
cytosolic Hsp70 chaperones and activates ssa1p ATPase
activity. Interacts with Hsp90 chaperones and inhibits
their ATPase activity

*Function derived from Saccharomyces Genome Database (SGD)
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2.1.2 Yeast Media
Table 5: Yeast growth media used in this study
Name

Composition

Description

YPD

10 g/L yeast extract, 20 g/L

Rich yeast media used for

peptone, 20 g/L glucose.

non-selective yeast growth
in liquid media or on agar
plates*.

Selective Dextrose

2% glucose, Yeast Nitrogen

Synthetic yeast media. Used

(SD)

Base (YNB), 6 g/L L-

for either non-selective yeast

isoleucine, 2 g/L L-arginine, 4

growth (when all selective

g/L L-lysine, 6 g/L L-

amino acids/uracil are

phenylalanine, 1 g/L L-

present) or for selective

threonine, 1 g/L L-methionine.

growth, when one of them is
absent.

Selective amino acids/uracil:

Can be used as liquid media

4g/L L-tryptophan, 6 g/L L-

or for agar plates*.

leucine, 2 g/L L-histidine, 2g/L
uracil.

Selective Glycerol

Same as SD, but 2% glycerol is

Synthetic yeast media. Used

used instead of glucose.

for yeast growth on glycerol
as a sole carbon source.

*23 g/L agar was used for preparing agar plates

2.1.3 E. coli Strains and Media
Escherichia coli Strain DH5α Genotype F–Φ80lacZΔM15 Δ(lacZYA-argF) 169
recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 was used in this
study. Subcloning Efficiency DH5α Competent Cells (Invitrogen, Cat. No. 18265-017)
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were used for the cloning work in this study. E. coli cultures were grown in Lysogeny
Broth (LB) medium (10 g/L NaCl, 10g/L tryptone, and 5 g/L yeast extract) with
antibiotic resistance (1X Ampicillin or Kanamycin depending on selectivity markers) for
transformations and cloning. 2x Yeast-typtone (2xYT) media (16 g/L tryptone, 10 g/L
yeast extract, and 5 g/L NaCl) was used for recovery of E. coli cells after transformation.

2.1.4 Mammalian Cell Lines and Media
Mouse neuroblastoma cells (N2a) and human neuroblastoma cells (SH-SY5Y)
were used in this study. Two different neuronal cell lines were used to avoid detecting
merely cell-line specific effects rather than a generally applicable phenomenon. Cells
were grown in Dulbecco's Modified Eagle Medium (DMEM, Corning) with 4.5 g/L and
supplemented with 10% fetal bovine serum (FBS, Gibco), 1X penicillin-streptomycin
solution (Corning), and 1X glutamine (Sigma Aldrich) at 37°C with ~5% CO2.

2.1.5 DNA Plasmids
Table 6: Plasmids used in this study
Plasmid
pDONR201

Purpose
Gateway cloning vector

Source
Invitrogen

pAG415GPD-Stop/YFP

Expression of DNAJC7

Susan Lindquist.

WT, missense mutations

Adgene number: 14146

and truncated variants in

(stop) 14218 (YFP)

yeast

p413MET25-TDP-43/FUS-

Expression of TDP-43 and

Stop

FUS; methionine
repressible

Susan Lindquist Lab
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2.1.6 Antibodies
Table 7: Antibodies used in this study
Antigen
GFP

Supplier
Sigma

Use
Western Blot

Concentration
1:1000

DNAJC7

Novus

Western Blot,

1:500

Immunohistochemistry

Histone 3

Abcam

Western Blot

1:1000

PGK-1

Thermofisher

Western Blot

1:2000

Scientific
𝛼Tubulin

Abcam

Western Blot

1:1000

DNAJA1

Novus

Western Blot

1:500

Rabbit Alexa

Thermofisher

Western Blot

1:1000

680

Scientific

Mouse Alexa

Thermofisher

Western Blot

1:1000

488

Scientific
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2.1.7 Additional Key Reagents
Table 8: Additional key reagents and chemicals used in this study
Reagent

Purpose

Source

L-azetidine-2-carboxylic

Protein misfolding stress

SigmaAldrich

acid (AZC)

induction

MG-132

Reversible inhibitor of 26s

SigmaAldrich

proteasome

Hydrogen Peroxide

Oxidizing agent. Induces

SigmaAldrich

protein, lipid, and nucleic
acid damage. Induces
oxidative stress response

Radicicol

Hsp90 inhibitor. Interferes

SigmaAldrich

with ATPase cycle of
Hsp90, thus preventing
proper Hsp90-mediated
protein folding

Enhanced

Highly sensitive method

Chemiluminescence (ECL)

for detecting proteins

Kit

bound to western blotting
membranes

BioRad
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DNAJC7 siRNA

To knockdown DNAJC7

Applied Biological

expression levels in N2a

Materials Inc.

cells

Gateway Cloning Kit

Cloning DNAJC7 into

Invitrogen

expression vector

Q5 Site-Directed

Production of DNAJC7

New England BioLabs

Mutagenesis Kit

mutation variants

(NEB)

QIAprep Spin Miniprep Kit

Isolation of DNA from E.

Qiagen

coli culture
PierceTM BCA Protein

Normalization of protein

ThermoFisher

Assay Kit

concentrations

Scientific

CellTiter-Glo Luminescent

Method for determining

Cell Viability Assay

the number of viable cells

Promega

in culture

2.1.8 Human Spinal Cord Tissue Samples
Table 9: Human spinal cord tissue samples
Tissue Sample
Intact human spinal cord

Purpose
3 sALS and 4 age-matched

samples

control samples. Used for
protein extraction and

Source
Strong Lab
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western blot probing of
DNAJ proteins

Formalin fixed and

Immunohistochemistry

Strong Lab

paraffin embedded human
lumbar spinal cord tissue
(sALS and control)

2.2 Experimental Methods
2.2.1 High Efficiency Yeast Transformation
Yeast transformations were performed according to standard PEG/lithium acetate method
protocol. A single colony of yeast cells are inoculated into 3 mL of YPD liquid or SD
media and incubated at 30°C with shaking overnight. The liquid culture is then combined
with 27 mL of YPD liquid to make a 30 mL liquid culture and incubated at 30°C shaking
till the cells have reached log phase (an OD600 of 0.4 to 0.5). The culture is then
centrifuged at 2000 xg for 5 minutes. The supernatant is aspirated off and the pellet is
washed with 3 mL of sterile water. The cells are centrifuged again at the same speed and
time. The pellet is resuspended in 2 mL of 100 mM Li-Acetate in TE buffer after the
wash step and incubated at 30°C shaking for 10 minutes. The culture is centrifuged again
after incubation and the pellet is resuspended in 100 μL of Li-Acetate per transformation.
Each transformation is composed of 100 μL cell suspension, 250 μL transformation (1 X
TE, 40% PEG, and 100mM Li-Acetate), 12μL salmon sperm DNA, 1μL (0.3~0.5 μg)
plasmid DNA, and 25μl DMSO and in the order listed and vortexed thoroughly. The cells
then recover at 30°C shaking for 30 minutes, following a 20-minute heat shock at 42°C
shaking. After heat shock, the cells are centrifuged for 1 minute at 2000 xg, the
supernatant aspirated, and the pellet resuspend in 100 μL TE buffer. The cells are then
plated onto selective agar plates.
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2.2.2 E. coli Transformation
We perform E. coli transformations to replicate and amplify plasmid DNA, resulting in
abundant amounts of DNA. 100 μL aliquots of transformation competent DH5α cells are
thawed on ice from storage at -80° C; 1-5 μL (0.1~0.5 μg) of plasmid DNA is added to
the cells and mixed thorough by gently flicking the tubes (the competent cells should not
be vortexed). The cells are allowed to recover on ice for about 30 mins and heat shocked
at 40°C for 45 seconds. The cells rest on ice for 2 mins before 1 mL of 2xYT is added
and the cells allowed to recover at 37° C in a shaking incubator for at least 1 hour.
Following recovery, the cells are centrifuged at 10,000 xg for one minute, the supernatant
aspirated off, and resuspend in 100 μl of 2xYT. The suspension is plated on LB agar
plates with selective antibiotic depending on the antibiotic resistance of the vector.

2.2.3 Cloning of DNAJC7 and Creation of DNAJC7 Mutation
Variants
2.2.3.1 Gateway Cloning
2.2.3.1.1 BP Reaction
The BP recombination reaction was performed by combining 2μl of destination vector
plasmid DNA (about 100- 200 ng of DNA) or PCR product, 1 μl of pDONR vector (150
ng/μl), and 2 μl of 5X BP Clonase (Invitrogen). The mixture is vortexed and centrifuged
twice to ensure thorough mixing and then allowed to incubate overnight at 30°C. 1 μl of
Proteinase K (Invitrogen) solution is added to the reaction following incubation and left
to react at 37° C for 10 minutes. 2 μl of this reaction mixture is then used to transform into
Subcloning Efficiency DH5α Competent Cells (Invitrogen, Cat. No. 18265-017)
following the protocol provided by the manufacturer. The cells are plated in LB
kanamycin (kan) resistant agar plates and incubated overnight at 37°C. Colonies are
picked from the plates and inoculated into LB kan liquid overnight at 37°C. The plasmids
are then extracted from the E. coli cells by using the High-Speed Plasmid Mini Kit
(Qiagen); the resulting DNA is in pDONR vector backbone.
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2.2.3.1.2 LR Reaction
The LR recombination reaction uses 1μl of the product (100-300 ng) from the BP
reaction, i.e. the pDONR vector, in combination with 2μl of destination vector (150
ng/μl), 13μl of TE buffer, and 4μl of LR Clonase (Invitrogen). The destination vectors
used are listed in section 2.1.4. The mixture is vortexed and centrifuged twice and
allowed to incubate overnight at 37°C. The resulting procedure is the same as described
for the BP recombination reaction—Proteinase K is added to the mixture, incubated, and
transformed into competent cells. The destination vectors are ampicillin (amp) resistant
and therefore must be plated on LB amp agar plates and then inoculated in LB amp liquid
media.

2.2.3.2 Cloning of Wild-type DNAJC7
DNAJC7 was PCR-amplified from a pUC-19 vector carrying a commercially-available
DNAJC7 transcript variant 1 cDNA human ORF (Sino Biological, Cat: HG20868-U).
The PCR product was cloned into pDONR201 vector (Table 5) using Gateway®
technology (Invitrogen) BP reaction and following the manufacturer’s protocols. The
correct sequence of the entry clones was confirmed by Sanger sequencing (performed by
Robarts London Regional Genomics Centre). DNAJC7 was cloned into p415GPDStop/YFP (Table 5) plasmid using the LR reaction. The identity of the destination vector
containing DNAJC7 was verified by restriction digest.

2.2.3.3 Cloning of DNAJC7 Mutation Variants
The wild-type pDONR201 DNAJC7 template (10 ng) was PCR amplified with Q5 Hot
Start High-Fidelity (Table 5) and non-overlapping mutagenetic primers in a 20uL
reaction. The resulting PCR products were ligated using the Kinase, Ligase, and Dpn1
(KLD) reaction and transformed into E. coli. Several colonies were then picked and
inoculated in 3mL of liquid LB Kan overnight. Cultures were then centrifuged, and DNA
was extracted from the pellets using the QIAprep Spin Miniprep kit (Table 5). The
presence of mutations was then verified by Sanger sequencing (performed by Robarts
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London Regional Genomics Centre). Mutated DNA was then cloned into p415GPDStop/YFP destination vector (Table 5) using the LR reaction. The identity of the
destination vector containing the mutated DNA was verified using restriction digest.

2.2.4 Spotting Assays
Yeast cells were inoculated in 3 mL of SD-complete liquid media and grown overnight in
a shaker-incubator at 30℃ and 200 rpm. Overnight cultures were diluted 1:10 in 1.5mL
microcentrifuge tubes and their OD600 was measured to determine cell density. In the row
A of a 96-well plate, the cultures were standardized by diluting them in sterile ddH2O to
OD600=1.0 and to a total volume of 200μL. The wells in the rows B-F were filled with
120μL of ddH2O, using a multichannel pipette. Subsequently, a 1:5 serial dilution was
performed by pipetting 30 μL of culture from each row above to the row immediately
below. Equal volumes of diluted culture from each well were transferred using a 48-prong
spotter onto dry agar plates, containing glucose, Glycerol or glucose + other chemicals
(Table 5). After all spotted liquid has been absorbed, the plates were incubated at 30℃ or
37℃ for 1-5 days, depending on the desired experimental conditions. At the end of the
incubation period, agar plates were imaged using the Bio-Rad ChemiDoc MP apparatus.

2.2.4.1 Spotting Assay Quantification
The growth of yeast cells was then quantified using mean gray value densitometry in
ImageJ software. The mean gray values of a single spot and of the plate background (no
yeast colonies present) were measured on a gray-scale, 8-bit image of a spotting assay. The
mean gray value of the background was subtracted from the mean gray value of the spot.
Those values were divided by the mean gray value of the positive control, yielding a value
that represents the relative amount of yeast cell growth for that dilution. Relative mean
growth values from three independent biological replicates were statistically analyzed to
identify any significant differences in growth between experimental and control groups.
Statistical analysis of the quantification results consisted of a one-way ANOVA followed
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by a post-hoc Tukey’s HSD test (95% confidence level) and was performed using the
RStudio software.

2.2.5 Live Cell Fluorescence Microscopy
Microscopy imaging of YFP tagged constructs was done by first inoculating yeast cells in
SD media at 30°C overnight. The cells are then washed twice with ddH2O, resuspended
in SD media, or various stress condition media (AZC, H2O2, and Radicicol) incubated at
30°C (37°C to induce heat stress). After inducing for 16 to 20 hours, 2uL of the liquid
culture are placed on a microscope slide. Fluorescence microscopy was performed using
the Cytation5 cell imaging multi-mode reader (BioTek, Winooski, WI, USA). LED cubes
and imaging filter cubes from biotech were employed for YFP tagged proteins: 465 LED
1225001 Rev J, GFP 469/525 1225101 Rev J, BioTekImages were captured on the 20×
objective. Image analysis was completed using the Gen5 imaging software (BioTek)

2.2.6 Western Blot
2.2.6.1 Alkaline Lysis of Yeast Cells
Liquid yeast cultures were grown overnight and centrifuged. The pellet was resuspended
in 100uL ddH2O and 100uL of 0.2 M NaOH and incubated at room temperature for five
minutes. The sample was then centrifuged, and the pellet was resuspended in 50uL of
SDS sample buffer (0.06 M Tris-HCl pH 6.8, 5% Glycerol, 2% SDS, 4% BME, 0.0025%
BromoPhenol Blue) and boiled for 3 minutes. The sample is then centrifuged for a final
time. The supernatant was obtained and loaded into the gel.

2.2.6.2 Mammalian Cell Lysis
Cells were washed with cold PBS which was then removed by aspiration. A cell scraper
was used to detach cells from culture plates into cold lysis buffer (50 mM Hepes pH 7.5,
150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100, and SIGMA FASTTM Protease
Inhibitor), after which cell lysates were frozen at -20°C. After thawing on ice, lysates
were subjected to a Branson Sonifier® ultrasonic cell disruptor for two 3-5 sec pluses.
Lysates were then centrifuged at 20000×g for 10 min at 4°C. The supernatants were
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obtained, and protein concentrations were determined using the BCA kit. The samples
were then loaded into the gel at the appropriate concentrations.

2.2.6.3 Normalization of Protein Concentrations (Mammalian
Cells)
We perform a BCA Protein Assay to determine the concentration of protein in the
sample. The assay was performed according to the Thermo Scientific Pierce BCA Protein
Assay Kit Instructions. After obtaining the concentration and normalizing the total
protein amount in each sample per blot, we dilute the samples with 4x reducing SDS
buffer (0.25M Trisma Base pH 6.8, 8.0% SDS, 40% sterile glycerol, 10% βmercaptoethanol, 0.04% bromophenol blue).

2.2.6.4 SDS-PAGE
We run SDS-PAGE with the samples on a 8-16% gradient gel (Bio-Rad Criterion TGX
Stain-Free Precast Gels) and/or 12% acrylamide gels at 220 V for about 30 mins. The gel
is then transferred onto a Nitrocellulose or PVDF membranes (BioRad) using the BioRad Trans-Blot Turbo machine following the manufacturer’s protocol. We then block the
membrane using 5% skim milk powder (Carnation) in Phosphate Buffered Saline with
0.01 % (v/v) Tween (PBST) and incubating for 1 hour on a shaker. The membrane is then
incubated in primary antibody overnight on shaker. Following incubation with the
primary antibody, we wash the membrane with 50mL aliquots of PBST at ten-minute
intervals for an hour on shaker and then incubate in the secondary antibody for 1 hour on
a shaker. The membrane is washed again with 50mL aliquots of PBST in ten minutes
intervals on shaker for an hour. The membrane is then documented using the ChemiDoc
MP System (Bio-Rad).

2.2.7 Mammalian Cell siRNA Transfection
Cells were grown to approximately 90% confluency in DMEM before transfecting cells
using Lipofectamine® 2000 (Thermo Fisher) for N2a cells following the supplier
recommended concentrations in Opti-MEM® low serum media. Cells were incubated
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with transfection reagents and plasmid DNA for 16-20 h at 37°C before washing with
PBS. Cells were returned to DMEM media to recover and allow expression of
recombinant proteins for 24 h before passaging into 6 well plates or 8 chamber
microscopy slides. Cells were grown for an additional 24 h after passaging before further
treatment or analysis.

2.2.8 Mammalian Cell Stress Treatment
Mammalian cells were treated with either 50 μM MG-132, 5 mM AZC, 1 mM H2O2, or
500 nM Radicicol for 16 h in DMEM at 37°C with 5% CO2. Following treatment, cells
were washed with PBS and used for western blotting or immunofluorescence microscopy
(IF).

2.2.9 Mammalian Cell Viability Assay
The CellTiter-Glo Luminescent Cell Viability Assay (Promega) was used in this study.
This assay delivers a highly sensitive read out of cellular fitness and is particularly useful
for studies on the toxicity associated with misfolded proteins. Transfected N2a cells are
split into 96 well plates and grown in minimum DMEM with 1% fetal bovine serum
(FBS, Gibco) and 1 g/L glucose. This minimal medium increases sensitivity to the toxic
effects of protein misfolding in many other systems, as well as differentiating N2a cells.
The cells are incubated at 37 °C for 20~24 hr. The cell viability assay is then performed
according to the supplier’s instructions. Plates were then measured using the Cytation 5
Cell Imaging Multi-Mode Reader (Biotek).

2.2.10 Immunofluorescence Microscopy
Following transfection, the cells are split into 8 well chambers (Labtek) and grown in
DMEM at 37°C for 20~24 hr. Each well is seeded with ca. 30,000 cells. The media is
then aspirated off and the cells washed 2 times with PBS. 4% paraformaldehyde is then
added to the wells to fix the cells for 15 min. This is followed by 3 washes in PBS. The
cells are permeablized with 0.5% TritonX-100 in PBS for 15 mins and washed with PBS
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3 times, followed by 5 washes in 0.5% BSA (Sigma) in PBS (PBB). We block nonspecific binding sites with 20% normal goat serum (Gibco) in PBB for 45 min. The cells
are then washed with PBB 5 times and incubated for an hour in anti-rabbit DNAJC7
primary antibody (Novus). We wash the cells with PBB 5 times and incubate for an hour
in α-rabbit texas red secondary antibody (Thermo Fisher). Following the secondary
antibody incubation, we wash in PBB 5 times. All the liquid is then aspirated off and
mounted with ProLong® Gold Antifade Mountant with DAPI. N2a cells were imaged
with the Cytation 5 Cell Imaging Multi- Mode Reader (Biotek).

2.2.11 Immunohistochemistry (IHC)
Immunohistochemistry was used to stain for DNAJC7. Slides were de-paraffinized in
xylene and rehydrated in 100% ethanol, 95% ethanol, 70% ethanol, ddH2O and quench
(20 mL 30% H2O2 and 180 mL methanol) to prepare them for staining. Antigen retrieval
was conducted in a pH 6 citrate buffer in a decloaking pressure chamber. Slides were
blocked for 30 minutes using 2.5% horse serum. They were then incubated overnight in
primary antibody solutions at 4°C. Rabbit anti-DNAJC7 polyclonal antibody (Novus,
1:500) was used as a primary antibody. Slides were then incubated with the ImmPress kit
horse-radish peroxidase micro-polymer solution and DNAJC7 was visualized using
Diaminobenzidine (DAB) solution incubation for 10 mins. Slides were stained with
hematoxylin, washed and then mounted and covered.

2.2.12 Protein Extraction Spinal Tissue Samples
Intact human spinal cord samples from sALs and neurotypical individuals were obtained
from the Strong Lab and stored in the -80°C freezer. Samples were then washed 3 times
with PBS to remove contaminants and ground into powder with a mortar and pistol in
liquid nitrogen. This powder (50mg) was suspended in 500uL of protein extraction buffer
(Tris 10 mM [pH 7.5], 500 mM NaCl 0.1%, Triton x-100, 1% β-mercaptoethanol and 1
mM PMSF) and 25uL of proteases and phosphatase inhibitor (Thermofisher). A 5mL
dounce homogenizer was used to homogenize the tissue. The homogenate was sonicated
for 5 minutes and then 100uL was divided into separate Eppendorf tubes. The protein
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concentrations were then determined using a BCA kit and the protein composition was
analyzed by resolving 20 μg of total protein content from each sample by SDS-PAGE
12% (Acrylamide).

2.2.13 Statistics
Statistical analysis of the yeast growth assays, viability assays, and the western blots were
done using excel. Statistical significance was obtained by performing unpaired t-tests to
compare the means and standard deviations between the control data set and the
experiment data set (each at a minimum of three biological replicas). Significance levels
are indicated using asterisks, where *** is p<0.001, ** is p<0.01, * is p<0.05.
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Chapter 3
3

Results

3.1 The DNAJC7 Yeast Model
The first aim of this project is to determine the function and localization of
DNAJC7. To this end, a yeast model expressing human DNAJC7 was established by
using a low copy (centromeric) vector with a constitutive promotor (GPD). We then
fused the human wild-type DNAJC7 to a yellow fluorescent protein (YFP, schematic is
shown in Figure 15A) on the carboxyl terminus of DNAJC7. Growth assays were
conducted with DNAJC7 and DNAJC7-YFP to determine if the YFP fusion alters the
growth phenotype of DNAJC7. Expression of both DNAJC7 and DNAJC7-YFP show no
growth defects in yeast compared to the vector control (Figure 15B, C). When the
DNAJC7-YFP expressing yeast cells were monitored by fluorescent microscopy a diffuse
localization was observed throughout the cytosol of the cell (Figure 15D). We used the
BY 4741 (MAT 𝛼) yeast strain, which is most commonly used for protein-misfolding
studies. Furthermore, all experiments in this study were performed with a minimum of
three distinct biological replicates (n=3).
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Figure 15. The DNAJC7 yeast model. A Schematic representation of the DNAJC7
fused with the yellow fluorescent protein (YFP). B Growth assay of yeast expressing
wild-type DNAJC7 and DNAJC7 fused to YFP on glucose media at 30°C. C
Quantification of growth assay in B (n=3). D Fluorescence microscopy image of
DNAJC7-YFP illustrating DNAJC7 localizes diffusely throughout the cytosol. Red box
indicates the magnification of a group of cells. Scale bar corresponds to 100𝜇m. The
large non-fluorescent area within the yeast cell is the vacuole.
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3.2 DNAJC7 Yeast Model Maintains Growth Phenotype and
Localization in Cells Exposed to Stress Conditions
In order to determine the function of a protein it can be useful to study its function
in the cell subjected to stress conditions. Thus, we monitored whether the growth
phenotype and localization of DNAJC7 changed following four stress conditions: heat
stress (37°C), protein misfolding stress (AZC), oxidative stress (H2O2), and Hsp90
inhibition stress (Radicicol). Yeast growth at 37°C leads to global cellular protein
misfolding, however, we did not observe a change in the growth phenotype of DNAJC7
(Figure 16A, B). Fluorescence microscopy of yeast cells expressing DNAJC7-YFP was
conducted following incubation at 37°C and we observed no change in localization in
comparison to cells grown at 30°C (Figure 16C).
Azetidine-2-carboxylic acid (AZC) is a proline analog that works by
competitively replacing proline residues during protein translation. Proteins that have
AZC incorporated can misfold and aggregate. We grow yeast cells expressing DNAJC7
on media containing 500𝜇m of AZC to observe any potential changes in DNAJC7 growth
phenotype. However, we do not observe any changes in the growth of yeast cells
expressing DNAJC7 in comparison to vector control (Figure 16D, E). At concentrations
greater than 500𝜇m AZC the yeast cells are unable to grow (Appendix A). Fluorescence
microscopy of DNAJC7-YFP expressing yeast cells was conducted and we observed no
change in localization in comparison to cells grown at 30°C (Figure 16F).
Next, we tested the function of DNAJC7 when subjected to oxidative stress
induced by hydrogen peroxide (H2O2). Oxidative stress refers to the imbalance of
reactive oxygen species (ROS) and the cell’s ability to detoxify ROS and counteract the
damages they cause. Oxidation of proteins may result in a change of conformation,
solubility, loss of function or gain of toxic function. While all amino acid residues are
susceptible to oxidation, cysteines are highly susceptible to oxidation due to their
nucleophilic thiol containing side chain (Turell et al., 2020). Utilizing in silico analysis
we determined that the cysteine content of DNAJC7 was approximately 2.8% (Gasteiger
et al., 2005). The average human protein contains 2.26% cysteine content, thus DNAJC7
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is fairly average (Miseta and Csutora, 2000). In order to test whether oxidative stress
affects DNAJC7 we created glucose plates infused with 100𝜇m H2O2 and performed
growth assays with a vector control and DNAJC7. We observed no change in DNAJC7
growth phenotype in comparison to the vector control when grown on media containing
100𝜇m of H2O2 (Figure 16G, H). Fluorescence microscopy of yeast cells expressing
DNAJC7-YFP was conducted and we observed no change in localization in comparison
to cells grown at 30°C (Figure 16I).
Radicicol is a natural product that binds to Hsp90s that renders this molecular
chaperone inactive (Schulte et al., 1999). It is speculated that the TPR domains in
DNAJC7 are important for interacting with the Hsp90 system (Brychzy et al., 2003).
Thus, we grew DNAJC7 expressing yeast cells on plates containing 100𝜇m of radicicol
and observed no change in growth in comparison to the vector control (Figure 16J, K).
Fluorescence microscopy of DNAJC7-YFP was conducted and we observed no change in
the localization in comparison to cells grown at 30°C (Figure 16L).
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Figure 16. Growth phenotype and localization of DNAJC7 remains unchanged
under various stress conditions. A Growth assay of yeast cells expressing DNAJC7
grown in glucose at 37°C. B Quantification of spotting assay in B. C Fluorescence
microscopy of DNAJC7-YFP expressing cells grown under normal conditions and grown
at 37°C for 6 hours before imaging. D Growth assay of DNAJC7 grown on media
containing 500𝜇m of AZC at 30°C. E Quantification of growth assay in D. F
Fluorescence microscopy of DNAJC7-YFP grown under normal conditions and media
containing 500𝜇m of AZC for 6 hours before imaging. G Growth assay of DNAJC7
grown on media containing 100𝜇m H2O2 at 30°C. H Quantification of growth assay in G.
I Fluorescence microscopy of DNAJC7-YFP grown under normal conditions and in
media containing 100𝜇m H2O2 incubated for 3 hours before imaging. J Growth assay of
DNAJC7 grown in media containing glucose and 100𝜇m Radicicol at 30°C. K
Quantification of growth assay in J. L Fluorescence microscopy of DNAJC7-YFP grown
under normal conditions and in media containing 100𝜇m radicicol for 4 hours at 30°C.
Red box indicates the magnification of a group of cells. Scale bar corresponds to 100𝜇m.
The large non-fluorescent area within the yeast cell is the vacuole.

3.3 Synthetic Growth Defect of DNAJC7 in Response to Ssz1
Deletion
The J-domain of DNAJC7 is important for interaction with Hsp70 (Brychzy et al.,
2003). Thus, we sought to determine which specific Hsp70s DNAJC7 might be
genetically interacting with. In other words, this would enable us to study the pathway of
protein quality control that DNAJC7 is involved in. We first collected all nine available
Hsp70 deletion strains from a yeast deletion library (Δssz1, Δssa1, Δssa2, Δssa3, Δssa4,
Δssb1, Δssb2, Δsse1, and Δsse2). Each of these deleted genes has a human homolog
(Kabani and Martineau, 2008). Growth assays were performed with each of the Hsp70
deletion strains expressing either DNAJC7 or a vector control (wild-type yeast cells
transformed with P415 GPD empty vector) under normal conditions (glucose, 30°C). We
observed diminished growth in Δssz1 yeast cells expressing DNAJC7, suggesting toxicity
of DNAJC7 (Figure 17A). The remaining eight Hsp70 deletion strains showed no change
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in growth when expressing DNAJC7 (Figure 17B-E). The growth phenotype was
determined to be statistically significant after quantification of the growth assays was
conducted (Figure 17F). Next, we determined if the localization of DNAJC7 changes in
the absense of each of the inidividual Hsp70 deletions. The localization of DNAJC7-YFP
remained diffuse throughout the cytosol in all Hsp70 deletion strains and thus did show
any changes compared to wild-type cells (Figure 18A-I).
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Figure 17. The deletion of Ssz1 leads to a synthetic growth defect in DNAJC7. A-E
Growth assays of all nine Hsp70 yeast deletion strains (Δssz1, Δssa1, Δssa2, Δssa3,
Δssa4, Δssb1, Δssb2, Δsse1, and Δsse2) expressing DNAJC7 and vector control at 30°C.
F Quantification of growth assays in A-E (n=3). Statistical analysis was performing using
a one-way ANOVA, followed by a Tukey’s test with a 95% confidence intervel (p<0.001
indicated by ***).
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Figure 18. The Localization of DNAJC7 remains unchanged with response to
various Hsp70 deletions.
A-I Fluorescence microscopy of DNAJC7-YFP in Hsp70 deletion strains grown in
glucose media at 30°C. Red box indicates the magnification of a group of cells. Scale bar
corresponds to 100𝜇m. The large non-fluorescent area within the yeast cell is the vacuole.

3.4 DNAJC7 Interaction with Hsp90 Chaperones
Next, we wanted to determine if DNAJC7 displays a change in growth phenotype
when Hsp90 chaperones are deleted. If a phenotype is detected this could indicate that the
intact Hsp90 system is required for the proper folding of DNAJC7 in the yeast model. We
expressed DNAJC7 in yeast cells that lacked either the Hsp82 encoding gene (Δhsp82) or
the Hsc82 encoding gene (Δhsc82). Δhsp82 is the Hsp90 allele activated in response to
cellular stress, whereas Δhsc82 is the constitutively expressed allele of Hsp90 in yeast
(Borkovich et al., 1989). Growth assays and fluorescence microscopy were performed in
Δhsp82 and Δhsc82 cells expressing DNAJC7 or DNAJC7-YFP to observe toxicity and
localization. The growth assays show no significant difference to vector control (Figure
19A, B). Fluorescence microscopy results show no significant difference in the diffused
cytosolic pattern of DNAJC7 in Δhsp82 or Δhsc82 cells when compared to wild-type
cells (Figure 19C, D).
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Figure 19. Hsp82/Hsc82 interaction with DNAJC7 in yeast. A Spotting Assay of
ΔHsp82 and ΔHsc82 yeast cells expressing DNAJC7. B Quantification of spotting assays
in A (n=3). C Fluorescence microscopy of DNAJC7-YFP in ΔHsp82 yeast cells under
normal conditions (glucose, 30°C). D Fluorescence microscopy of DNAJC7-YFP in
ΔHsc82 yeast cells under normal conditions (glucose, 30°C). Red box indicates the
magnification of a group of cells. Scale bar corresponds to 100𝜇m.
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3.5 DNAJC7 Interaction with Hsp90 Co-chaperones
We next tested the effect of the Hsp90 co-chaperones Cdc37 and Sti1 on DNAJC7
toxicity, and localization.

3.5.1 DNAJC7 is Able to Rescue the Growth Defect of DAmP Cdc37
In Yeast Cells
Cdc37 is an Hsp90 co-chaperone important for presenting client proteins to
Hsp90 for their proper protein folding. Cdc37 is essential for the survival of yeast and
cannot be deleted from its genome, therefore yeast cells lacking Cdc37 expressing
DNAJC7 could not be obtained (Calderwood, 2015). As a result, we utilized decreased
abundance by mRNA perturbation (DAmP) Cdc37 yeast cells. DAmP yeast strains
contain compromised alleles of essential genes that exhibit modest growth defects. We
utilized this strain to observe the toxicity and localization of DNAJC7 in response to
decreased levels of Cdc37 in the cell and determine whether or not DNAJC7 can
compensate for the decreased abundance of Cdc37 in the yeast model. Under optimal
yeast growth conditions (glucose, 30°C) DAmP Cdc37 cells expressing an empty vector
show a slight growth defect compared to wild-type cells (Figure 20A, B). This result is
recapitulated at 37°C (Figure 20C, D). This growth defect is partially rescued when
DNAJC7 is expressed in DAmP Cdc37 cells as shown by the decreased growth defect in
comparison to DAmP Cdc37 empty vector (Figure 20A, B). This result is also
recapitulated at 37°C (Figure 20C, D). Fluorescence microscopy results for DNAJC7YFP expressed in DAmP Cdc37 cells show no change in the diffused cytosolic pattern
when compared to wild-type cells at 30°C (Figure 20E).
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Figure 20. DNAJC7 is able to rescue the growth phenotype associated with DAmP
Cdc37. A Growth assay of wild-type and DAmP Cdc37 yeast cells expressing DNAJC7
under normal growth conditions (glucose, 30°C). B Quantification of the growth assay in
A (n=3). C Growth assay of wild-type and DAmP Cdc37 yeast cells expressing DNAJC7
under heat stress conditions (glucose, 37°C). D Quantification of the growth assay in C
(n=3). E Fluorescence microscopy of DNAJC7-YFP in DAmP Cdc37 yeast cells grown
in glucose at 30°C. Red box indicates the magnification of a group of cells. Scale bar
corresponds to 100𝜇m.

3.5.2 DNAJC7 Interaction with Sti1
Sti1 is an Hsp90 co-chaperone protein that mediates the transfer of client proteins
from Hsp70 to Hsp90. In order to confirm that DNAJC7 does not perform the function of
Sti1 we expressed DNAJC7 in ∆Sti1 yeast and conducted spotting assays at 30°C and
37°C (Figure 21A, C). It has been published in the literature that ∆Sti1 displays a
significant growth defect under 37°C (Hoseini et al., 2016), and the goal of this
experiment was to determine whether DNAJC7 could rescue this defect. However, it
appears that the ∆Sti1 strain used may have undergone a spontaneous mutation
preventing it from displaying a growth phenotype at 37°C, please refer to the limitations
section 4.5.2 of the thesis. The results showed that under both growth temperatures ∆Sti1
yeast did not display a toxic phenotype, and the addition of DNAJC7 did not change this
phenotype (Figure 21A-D). Furthermore, the fluorescence microscopy results for
DNAJC7 expressed in ∆Sti1 cells show no change in the diffused cytosolic pattern when
compared to wild-type cells at 30°C (Figure 21E).
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Figure 21. Sti1 and DNAJC7 interaction in yeast. A Growth assay of wild-type and
∆Sti1 yeast cells expressing DNAJC7 under normal growth conditions (glucose, 30°C). B
Quantification of the growth assay in A (n=3). C Growth assay of wild-type and ∆Sti1
yeast cells expressing DNAJC7 under heat stress conditions (glucose, 37°C). D
Quantification of the spotting assay in C (n=3). E Fluorescence microscopy of DNAJC7YFP ∆Sti1 yeast cells grown in glucose at 30°C. Red box indicates the magnification of a
group of cells. Scale bar corresponds to 100𝜇m.
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3.6 DNAJC7 Rescues the Toxicity of FUS and TDP-43 in Yeast Cells
FUS and TDP-43 are both well characterized ALS-associated misfolded proteins.
Previous studies and unpublished data from our lab have shown that TDP-43 and FUS
toxicity in yeast is associated with their propensity to misfold, aggregate, and interfere
with cellular processes. The molecular chaperones important for the proper folding of
FUS/TDP-43 has not yet been determined. Thus, we tested whether DNAJC7 chaperone
aids in the proper folding of FUS and TDP-43 and thus reduces their toxicity. We first
obtained FUS and TDP-43 constructs under the control of a methionine-repressible
promoter (Valastyan and Lindquist, 2011) (Figure 22A). This relatively weak promoter
was used instead of a strong constitutive promotor (GPD) to restrict the expression of
highly toxic proteins (FUS and TDP-43) during yeast transformations and growth.
Next, we transformed each of these constructs with DNAJC7 and performed
growth assays under non-repressed (no methionine in media) and repressed (methionine
added to media) conditions on glucose media (Figure 22B). These growth assays showed
a significant decrease in toxicity of cells co-expressing FUS or TDP-43 with DNAJC7 in
comparison to FUS or TDP-43 co-expressing an empty vector control under nonrepressed conditions (Figure 22B, C). This significant decrease in toxicity is also
observed under glycerol conditions, where cells respire, in both repressed and nonrepressed media (Figure 22D, E). Fluorescence microscopy results show no significant
difference in the cytosolic diffused pattern of DNAJC7 in FUS (Figure 22F) or TDP-43
yeast cells (Figure 22G).
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Figure 22. DNAJC7 rescues the growth toxicity of FUS and TDP-43 in yeast cells. A
Growth assays of yeast cells expressing DNAJC7 and FUS or TDP-43 (non-repressed)
under normal conditions (glucose, 30°C). C Quantification of growth assays in B (n=3).
Statistical analysis was dperforming using a one-way ANOVA, followed by a Tukey’s
test with a 95% confidence intervel (p<0.001 indicated by ***, p<0.05 indicated by *). D
Growth assays of yeast cells expressing DNAJC7 and FUS or TDP-43 (non-repressed)
grown on glycerol at 30°C. E Quantification of growth assays in D (n=3). Statistical
analysis was performing using a one-way ANOVA, followed by a Tukey’s test with a
95% confidence intervel (p<0.001 indicated by ***). F Flourescence microscopy of
DNAJC7-YFP in yeast cells expressing FUS (non-repressed) and DNAJC7 under normal
conditions (glucose, 30°C). G Fluorescence microscopy of DNAJC7-YFP in yeast cells
expressing TDP-43 (non-repressed) and DNAJC7 under normal conditions (glucose,
30°C). Red box indicates the magnification of a group of cells. Scale bar corresponds to
100𝜇m.

3.7 DNAJC7 May Require Hsp90 to Rescue the Growth Defect
Associated with TDP-43 and FUS
Next we wanted to determine whether the ability of DNAJC7 to rescue the growth
toxicity of FUS and TDP-43 in yeast cells requires Hsp90 chaperones. In yeast cells
lacking the hsp82 encoding gene (Δhsp82) or hsc82 encoding gene (Δhsc82), growth
assay results indicate that the addition of DNAJC7 can no-longer rescue the growth
toxicity induced by FUS or TDP-43 under both repressed (methionine) (Figure 23A, C)
and non-repressed (methionine minus) conditions (Figure 23A, E). Furthermore,
DNAJC7 can no-longer rescue the growth toxicity induced by FUS or TDP-43 in yeast
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cells lacking Hsp82 or Hsc82 under glycerol (respiratory) conditions of repressed
(methionine) (Figure 23B, D) and non-repressed (methionine minus) (Figure 23B, F).
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Figure 23. DNAJC7 may require Hsp90 to rescue the growth toxicity of FUS and
TDP-43 in yeast cells. A Growth assays of ΔHsp82 or ΔHsc82 yeast cells co-expressing
DNAJC7 and FUS or TDP-43 (non-repressed) under normal conditions (glucose, 30°C).
B Growth assays of ΔHsp82 or ΔHsc82 yeast cells co-expressing DNAJC7 and FUS or
TDP-43 (non-repressed) grown on glycerol at 30°C. Quantification of growth assays in A
(n=3) C Quantification of glucose repressed (methionine) growth assays in A (n=3)
normalized to wild-type control. D Quantification of glycerol repressed (methionine)
spotting assays in B (n=3) normalized to wild-type control. E Quantification of glucose
non-repressed (methionine minus) growth assays in A (n=3) normalized to wild-type
control. F Quantification of glycerol (respiratory) non-repressed (methionine minus)
growth assays in B (n=3) normalized to wild-type control. Statistical analysis was
performing using a one-way ANOVA, followed by a Tukey’s test with a 95% confidence
intervel (p<0.001 indicated by ***, p<0.01 indicated by **, and p<0.05 indicated by *).

3.8 DNAJC7 ALS-Associated Mutations
Next we genetically engineered expression vectors for ALS-associated DNAJC7
missense mutations.

3.8.1 DNAJC7 Missense Mutations
A recent study uncovered that DNAJC7 in ALS individuals is associated with four
missense mutations, which result in the following amino acid changes: D8H, D211N,
R412W, and E425K (Farhan et al., 2019). To test the effects of these ALS-associated
missense mutations we first analyzed them in silico using a software called Sorting
Intolerant from Tolerant (SIFT). SIFT predicts whether an amino acid substitution of an
individual amino acid changes the structure of a protein. The results of SIFT show that
pR412W is the only missense mutation of the four listed above that is predicted to have a
severe effect on the function of DNAJC7 (Figure 24). pD211N and pE425K are predicted
to conserve the protein function and structure is likely to be tolerated by the cell (Figure
24). Conversely, the pD8H mutation was found to be conserved based on the properties
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of the amino acids. However, SIFT was not able to predict whether pD8H would be
tolerated or deleterious because the algorithm could not find any closely related
homologous sequences for this particular region (Figure 24) which raises doubt about the
validity of this prediction.
Next, we genetically engineered the expression vectors for the following three
DNAJC7 mutations, pD211N, pR412W, and pE425K (Figure 25A) and transformed
them into yeast cells. We first wanted to determine if these mutations lead to a toxic
growth defect. Thus, we performed a growth assay with all three of the DNAJC7
mutations as well as their YFP counterparts, which showed no significant growth defects
when compared to WT DNAJC7 (Figure 25B, C). In order to confirm whether or not the
protein is being degraded by the cell we performed a western blot on yeast lysates
expressing DNAJC7, pR412W or pE425K and probed for DNAJC7. The results of the
western blot demonstrate that the steady-state protein levels of R412W and E425K are
reduced compared to wild-type DNAJC& and may be degraded (Figure 25D). However,
the YFP fused mutation constructs of pR412W and pE425K show similar state-state
levels as wild-type DNAJC7 according to the results of the western blot probed with an
anti GFP antibody (Figure 25E). Fluorescent microscopy further confirms that the YFP
fused constructs are not degraded in the cell and that the localization does not change
compared to WT DNAJC7 (Figure 25F).
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Figure 24. In silico predicted effects of ALS-associated DNAJC7 mutations. SIFT
predictions of amino acid substitutions in DNAJC7. Scores less than 0.05 are predicted to
affect the protein function. Scores greater than 0.05 are predicted to be tolerated and less
likely to affect the proteins function.
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Figure 25. Establishing ALS-associated DNAJC7 missense mutations in the yeast
model. A Schematic representation of the ALS-associated DNAJC7 missense mutations
pD211N, pR412W, and pE425K. B Growth assay of yeast cells expressed each DNAJC7
missense mutation (pD211N, pR412W, and pE425K) as well as the YFP fusion under
normal growth conditions (glucose, 30°C). C Quantification of spotting assay in B (n=3).
D Western blot showing DNAJC7 expression level in yeast cells expressing either
DNAJC7, pR412W, or pE425K. (Full western blots shown in Appendix A) E Western
blot showing expression levels in yeast cells expressing either DNAJC7-YFP, pR412WYFP, or pE425K-YFP. (Anti-GFP antibody recognizes YFP) (full western blots shown in
Appendix A). F Fluorescence microscopy of DNAJC7 missense mutations pD211N,
pR412W, and pE425K fused to YFP under normal conditions (glucose, 30°C). Red box
indicates the magnification of a group of cells. Scale bar corresponds to 100𝜇m.

3.8.2 DNAJC7 Truncations
According to a recent study DNAJC7 in ALS individuals is associated with four
nonsense variants that can lead to the following truncated proteins: pE33X, pQ120X,
pR156X, and pR216X (Farhan et al., 2019). (X indicates the premature stop codon
inserted by the mutation). Thus, we genetically engineered expression vectors for the
following three DNAJC7 truncation variants, pE33X, pQ120X, and pR216X (Figure
26A) and transformed them into yeast cells. Furthermore, we genetically engineered a
DNAJC7 truncation construct lacking the J-domain, pK380X (Figure 26A). First, we
performed a growth assay with yeast cells expressing these DNAJC7 truncations, which
showed no significant growth defect when compared to WT DNAJC7 (Figure 26B, C).
Fluorescent microscopy results indicate that the localization remained diffused
throughout the cytosol in all four truncation variants (Figure 26D).
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Figure 26. Establishing ALS-associated DNAJC7 truncations in the yeast model. A
Schematic representation of the ALS-associated DNAJC7 truncations (pE33X, pQ120X,
and pR216X) and truncation designed to remove functional J-domain of DNAJC7
(pK380T). B Spotting assay of yeast cells expressing each of the DNAJC7 mutations
pE33X, pQ120X, pR216X, and pK380T under normal conditions (glucose, 30°C). C
Quantification of the spotting assay in B (n=3). D Fluorescence microscopy of DNAJC7
truncations fused with YFP under normal conditions (glucose, 30°C). Red box indicates
the magnification of a group of cells. Scale bar corresponds to 100𝜇m.
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3.9 Mammalian Cells
We sought to validate our yeast results in mammalian cells. Human
neuroblastoma cells, SH-SY5Y, displayed low protein expression of DNAJC7 (Figure
27A). Therefore, we chose to proceed utilizing mouse neuroblastoma, N2a cells. The
results are shown in the following sections.

3.9.1 Endogenous DNAJC7
First, we performed western blot analysis to determine the endogenous protein
levels of DNAJC7 in both N2a, and SH-SY5Y cells (Figure 27A). The endogenous
expression of DNAJC7 in SH-SY5Y cells is less abundant in comparison to N2a cell
(Figure 27A). Full western blots are shown in Appendix A. Microscopy results of N2a
cells show that DNAJC7 is localized and diffused throughout the cytosol (Figure 27B).
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Figure 27. Endogenous DNAJC7 in N2a and SH-SY5Y cells.
A Western blot showing endogenous DNAJC7 expression levels in N2a and SH-SY5Y
cells. (Full western blots in Appendix A) B Immunofluorescence microscopy of
endogenous DNAJC7 in N2a cells (p-12 indicates the cell passage number is 12).
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3.9.2 DNAJC7 Knock Down Under Various Stress Conditions
Small interfering RNA (siRNA) was used to knock down the expression of
DNAJC7 in N2a cells. The knockdown was verified using a western blot probed for
DNAJC7 in cells transfected with siRNA or scrambled control siRNA (Figure 28A) (full
western blot in Appendix A). After confirming a successful knock down of DNAJC7 a
luciferase-based assay was performed to access the viability of N2a cells transfected with
siRNA against DNAJC7 or scrambled control siRNA treated with various stress
conditions for 16 hours (Figure 28B). The results of this experiment will aid in
determining the importance of DNAJC7 to the viability of N2a cells under cellular stress.
We observed that control (scrambled), untreated cells display a greater viability
compared to siRNA against DNAJC7, untreated cells. Furthermore, control scrambled
cells treated with 50𝜇m of MG-132 (proteasome inhibitor) also display a greater viability
compared to siRNA against DNAJC7 transfected cells. The remaining three stress
treatments (5mM AZC, 1mM H2O2, and 500nM radicicol) show no difference between
siRNA against DNAJc7 or control scrambled cells (Figure 28B). Next, we determined the
protein levels of DNAJC7 in siRNA against DNAJC7 and control scrambled N2a
transfected cells treated with 5mM AZC, 50𝜇m MG-132, 1mM H2O2, and 500nM
radicicol. We performed western blots with the control scrambled cell lysates and with
the siRNA against DNAJC7 cell lysates (Figure 28C) (Full western blots in Appendix A).
After quantifying the western blots, the results indicate that treating scrambled N2a cells
with 500nM radicicol leads to a significant increase in DNAJC7 protein concentration in
comparison to the siRNA transfected cells (Figure 28D).
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Figure 28. DNAJC7 knock down in N2a cells treated with various stress conditions.
A Western blot showing siRNA knock down of DNAJC7 in N2a cells in comparison to
scrambled control. A yeast lysate and untreated N2a cell lysate were used as controls. B
Normalized to untreated scrambled control luciferase viability assay of siRNA knock
down of DNAJC7 and scrambled control treated with various cellular stress conditions
(5mM AZC, 50𝜇m MG-132, 1mM H2O2, and 500nM Radicicol). C Western blots
displaying DNAJC7 siRNA were grown in media treated with 5mM AZC, 50uM MG132, 1mM H2O2, and 500nM radicicol for 16 hours before blot in C normalized to the
loading control (Histone 3). Statistical analysis was performing using a one-way
ANOVA, followed by a Tukey’s test with a 95% confidence intervel (p<0.001 indicated
by ***). (Full western blots in Appendix A).

3.10 Immunohistochemistry
The anterior gray horn of the human spinal cord harbours the cell bodies of alpha
motor neurons (Figure 29A). Immunohistochemical analysis of the anterior horn of the
spinal cord from neurologically normal individuals and individuals diagnosed with
sporadic ALS (sALS) showed DNAJC7 diffused throughout the cytosol of motor neuron
cells in both cases (Figure 29B).
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Figure 29. Localization of DNAJC7 remains cytosolic in the anterior horn of the
human spinal cord of sALS patients. A Schematic of the anterior horn of the human
spinal cord. B Immunohistochemistry images of the anterior horn of the human spinal
cord from unaffected (control) and Sporadic ALS patients stained for DNAJC7 (1:500).
Arrow heads show motor neurons.

3.11 DNAJC7 Extraction from Human Spinal Cord Tissue
To further understand DNAJC7 expression we extracted proteins from human
spinal cord samples of neurologically normal and sALS individuals. Once the proteins
lysates were prepared, we ran a western blot and probed for DNAJC7, which displayed
an increase of lower molecular weight species in sALS patient sample in comparison to
the control sample (Figure 30A). In order to specify whether the accumulation of lower
molecular weight species seen in the sALS sample was a DNAJC7 specific phenomena
we used the same protein samples and probed for DNAJA1, another J protein expressed
in human neurons (Figure 30B). The blot for DNAJA1 only displays a similar pattern of
increased lower molecular weight species in sALS samples in comparison to control
(Figure 30B).
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B
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Figure 30. Endogenous DNAJC7 and DNAJA1 levels in neurologically normal
individuals (control) and sALS patient spinal cord tissue. A Endogenous DNAJC7
(57 kDa) levels in unaffected (control) and Sporadic ALS patient spinal cord tissue B
Endogenous DNAJA1 (45 kDa) levels in unaffected (control) and sporadic ALS (sALS)
patient spinal cord tissue. (Full western blots shown in Appendix A).
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Chapter 4
4 Discussion
4.1 Determining the Function of DNAJC7
4.1.1 Localization and Expression of DNAJC7
A tissue-based map of the human proteome has shown that DNAJC7 is
ubiquitously cytosolic in human tissue and cultured cells, under normal growth
conditions (Uhlen et al., 2015). We recapitulated these results in yeast (Figure 15D),
mammalian cells (Figure 27B), and pathological specimens (Figure 29B). Our findings
further indicate that DNAJC7 remains cytosolic under various stress conditions in yeast
(Figure 16) and in human tissue samples of individuals affected by sALS (Figure 29). We
analyzed four specific stressors in yeast including, heat stress (37°C), protein-misfolding
stress (AZC), oxidative stress (H2O2), and Hsp90 inhibition stress (radicicol). Under
stress conditions the cell attempts to maintain proteostasis, which usually involves the
activation of the heat shock response (HSR) (Verghese et al., 2012). This upregulates the
expression of many molecular chaperones. In some cases, these chaperone proteins relocalize to different cellular compartments, particularly the nucleus, in order to protect
essential cellular machinery from damage. In fact, some DNAJ proteins have been shown
to re-localize to the nucleus from the cytoplasm in metazoans under acute proteotoxic
stress (Shibata and Morimoto, 2014). However, our data indicates that DNAJC7 does not
change its localization under stress conditions (Figure 16C, F, I, L), indicating that
DNAJC7 may not be required for maintaining protein quality control in the nucleus under
all proteotoxic stress conditions we tested.

4.1.2 DNAJC7 Interaction with the Hsp70 System
As previously mentioned DNAJC7 contains a J-domain located at the c-terminus
that is responsible for increasing the ATPase activity of Hsp70 (Brychzy et al., 2003).
The literature recognizes that DNAJC7 interacts with cytosolic Hsp70s (Li et al., 2015),
however, our data indicates that DNAJC7 may also genetically interact with the
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ribosomal Hsp70s (i.e. Ssb1/2, Ssz1). Ribosomal Hsp70s are part of the RAC (Ribosome
Associated Complex) and are responsible for folding nascent polypeptides emerging from
the ribosome. As seen in our results DNAJC7 experiences a toxic growth phenotype in
the absence of Ssz1(Figure 17A). This may indicate that Ssz1 is part of the yeast cellular
machinery responsible for folding DNAJC7 and thus in the absence of Ssz1 DNAJC7
cannot fold properly becoming toxic to the environment of the cell. An alternative
explanation is that in the absence of Ssz1, DNAJC7 may interact with another component
of the translation associated protein folding machinery such that it can no longer perform
its proper function in the cell. This is further corroborated by research from our lab that
showed a physical interaction between DNAJC7 and Ssb1(Sandhu, 2019 unpublished).
Thus, in the absence of Ssz1 DNAJC7 may interact more strongly with Ssb1 thus
precluding it from performing its normal functions. We did not observe a similar growth
defect in the deletion strains of the remaining yeast Hsp70s (Ssa1/2, Ssa3/4, Ssb1/2,
Sse1/2), expressing DNAJC7 (Figure 17 B-F). However, the many different cytosolic
Hsp70s are highly similar in expression and function. Therefore, the function of one of
these deleted Hsp70s would likely be replaced by its corresponding paralog, which would
not allow to unravel any specific genetic interactions.

4.1.3 DNAJC7 Interaction with the Hsp90 System
DNAJC7 possesses two TPR domains, which typically regulate interactions with
the Hsp90 system. Accordingly, multiple studies have shown that DNAJC7 binds to
Hsp90; this interaction is particularly strong with Hsp90AA1 (Brychzy et al., 2003;
Cintrón Moffatt et al., 2008; Taipale et al., 2014). However, the mechanistic function that
DNAJC7 may be preforming with Hsp90 has yet to be discovered. It has been shown that
DNAJC7 cannot substitute the knockdown of Hop (human homolog of Sti1) in N2a cells,
indicating that DNAJC7 cannot perform Sti1-specific functions, which is connecting the
Hsp90 and Hsp70 chaperone systems. Our data indicates that DNAJC7 may perform
functions that overlap with Cdc37 (Figure 20). Cdc37 is an essential Hsp90 co-chaperone
important for presenting client proteins, particularly kinases, to Hsp90 for their proper
protein folding (Verba and Agard, 2017). Unlike Sti1, Cdc37 does not contain a TPR
domain, which is utilized by Sti1 to facilitate the delivery of client proteins to Hsp90 as
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well as to conduct the Hsp70/Hsp90 bridging interaction (Silverstein et al., 1998). Rather,
Cdc37 binds at a different region of Hsp90 that overlaps with the binding site of the
Sti1’s TPR binding site (Silverstein et al., 1998). When the abundance of Cdc37 is
decreased through mRNA perturbation in yeast cells possessing, a growth defect is
observed (Figure 20A, B, C, D), indicating the important function of CDC37 in protein
quality control. However, with the addition of DNAJC7 we notice a rescue of this growth
phenotype, indicating that DNAJC7 may be able to recruit Cdc37-specific client proteins,
potentially utilizing one or both of its TPR domains to bind to the TPR binding site on
Hsp90 and perform Cdc37-specific functions. This is further supported by the
observation that DNAJC7 chaperones Chk1 kinase in vitro, and as mentioned earlier
kinases are client-proteins of Cdc37 (Cintrón Moffatt et al., 2008).
Furthermore, our cell culture data indicates that DNAJC7 protein expression
increases in cells treated with radicicol, an Hsp90 inhibitor (Figure 28C-D). This may
suggest that Hsp90 clients are accumulating in cells treated with radicicol and the cell is
attempting to compensate for this toxicity by upregulating DNAJC7 expression. Thus, we
propose that DNAJC7 and Hsp90 are involved in processing the same or at least similar
client proteins.

4.2 The Role of DNAJC7 in Folding ALS-associated Proteins, TDP-43
and FUS
As shown in the literature yeast lack the cellular machinery necessary to properly
fold human TDP-43 and FUS. As a result these proteins misfold, aggregate, and interfere
with cellular processes in yeast (Di Gregorio and Duennwald, 2018). Interestingly, my
data indicates that expression of DNAJC7 is able to rescue the toxic growth phenotype
caused by FUS and TDP-43 expression (Figure 22B-E). However, when the same
experiment was performed in yeast strains with reduced expression of Hsp90, the ability
of DNAJC7 to rescue TDP-43 and FUS toxicity was impaired (Figure 23). This suggests
that DNAJC7 may be facilitating the proper folding of TDP-43 and FUS through the use
of Hsp90. Furthermore, yeast cells expressing TDP-43/FUS and DNAJC7-YFP fusions
display a diffuse YFP signal in the cytosol (Figure 22F-G), illustrating that DNAJC7 does
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not localize to the FUS/TDP-43 toxic aggregates formed in cells. Lack of co-localization
to the aggregates may indicate that DNAJC7 is not responsible for disaggregating TDP43/FUS, but rather DNAJC7 may prevent the formation of toxic aggregates or toxic
interaction with other proteins.
According to a high-throughput proteomics study, DNAJC7 and FUS physically
interact (Li et al., 2015). Thus, DNAJC7 may be binding to FUS and connect it to
components of the yeast chaperone machinery (i.e. Hsp90) for proper folding or
preventing toxic interactions. Conversely, the mechanism behind DNAJC7 rescuing
TDP-43 toxicity is less straight forward considering there has been no physical
interaction detected between these two proteins so far (Li et al., 2015). We propose three
ways in which DNAJC7 could be rescuing TDP-43 toxicity: first, the expression of
DNAJC7 could aid in a downstream effect responsible for reducing TDP-43 toxicity;
second, DNAJC7 and TDP-43 may interact transiently, which would explain why this
physical protein-protein interaction was not detected by the high-throughput proteomics
study; third, DNAJC7 and TDP-43 may interact through intermediate proteins, for
instance Hsp70 and/or Hsp90. In fact, our third point is further supported as Hsp70 has
been shown to prevent aggregation of TDP-43 (Kitamura et al., 2018) and Hsp90 has
been shown to bind to TDP-43 (Zhang et al., 2010).
One function for DNAJC7 proposed in the literature involves a client protein that
has not yet properly folded through a single cycle of the Hsp70/Hsp90 system being
passed back from Hsp90 to Hsp70 by DNAJC7, in a reverse Sti1 manner, to complete the
folding cycle (Brychzy et al., 2003). Thus, given the interaction between DNAJC7 and
Hsp90, DNAJC7 may be reducing the toxicity of TDP-43 and FUS by passing them from
Hsp90 to Hsp70 to be folded properly.
TDP-43 and FUS are categorized as aggregation prone proteins and partially
folded states of these proteins increase their propensity towards aggregation. Both TDP43 and FUS contain a prion-like domain (PrLD) and an RNA-binding domain (RRM).
Typically, the interactions between PrLDs are responsible for liquid-liquid phase
separation and aggregation (Patel et al., 2015), however, other parts of the protein i.e.
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RRM2 in TDP-43 and RGG2 in FUS, also facilitate these processes (Bogaert et al., 2018;
Conicella et al., 2020). In TDP-43, the RRM2 domain contains hydrophobic amino acids
and it has stable folding intermediates which are more prone to aggregation than the
native protein (Tavella et al., 2018). Thus, chaperone proteins may be important for
properly folding these aggregation prone folding intermediates. Conversely, FUS
contains an RRM domain in which the energetic barrier between folded and unfolded
states is very low, indicating that chaperones may be required to stabilize the folded
conformation (Lu et al., 2017). We speculate that folding through the Hsp70/Hsp90
system with the aid of DNAJC7 may be required for TDP-43 and FUS to prevent their
transition to the aggregated state. Alternatively, Hsp70 and DNAJC7 may be responsible
for recognizing TDP-43 and FUS folding intermediates for proteasomal degradation
(Chen et al., 2016). Our speculation that DNAJC7 plays a unique role in folding and/or
degrading proteins prone to aggregation is further supported by the observation that
overexpression of DNAJC7 reduces toxicity of PolyQ proteins in the Drosophila eye
model (Kazemi-Esfarjani and Benzer, 2000).

4.3 Creating a Yeast Model for ALS-associated DNAJC7 Missense
and Nonsense Mutations
4.3.1 In Silico Predictions of DNAJC7 Missense Mutations
A recent study uncovered that four missense mutations in the gene encoding
DNAJC7 are associated with sALS (protein change: D8H, D211N, R412W, and
E425K)(Farhan et al., 2019). To test the effects of these ALS-associated missense
mutations, we first analyzed them in silico using a software called Sorting Intolerant from
Tolerant (SIFT) (Ng and Henikoff, 2003). SIFT predicts whether an amino acid
substitution affects the protein folding based on sequence homology and the physical
properties of each individual amino acid within the context of the whole protein. The
results of SIFT show that pR412W is the only missense mutation of the four listed above
that is predicted to have a severe effect on the proper protein folding of DNAJC7 (Figure
24). Interestingly, this particular amino acid substitution is located within the J-domain of
DNAJC7 and immediately adjacent to the highly conserved tripeptide histidine, proline,
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and aspartic acid (HPD) motif. The HPD motif is critical for the function of the J-domain
to increase the ATPase activity of Hsp70. It is important to note that the HPD motif and
its adjacent residues are located within an exposed loop region that are hydrophilic in
nature. Thus, substituting arginine, which is positively charged and hydrophilic, for
tryptophan, which is hydrophobic, would likely affect the proper position of the loop
region. Furthermore, this particular arginine residue has been recognized in the literature
as an essential side-chain residue within DNAJC7 and a substitution with glycine, which
is non-polar and hydrophobic, will disable the J-domain function (Genevaux et al.).
pD211N and pE425K are predicted to conserve DNAJC7 structure (Figure 24),
however, SIFT does not predict whether or not the function of the protein will be
impaired. pD211N is located within the flanking region of the pS207 phosphorylation site
of the second TPR domain. Maintaining the flanking region of the phosphorylation site is
critical for its recognition by protein kinases (Ubersax and Ferrell, 2007). Interestingly,
Sti1 has been shown to be regulated by three phosphorylation sites within its TPR
domains. Upon phosphorylation of these sites, Sti1 experiences a decrease in transfer
efficiency of clients from Hsp70 to Hsp90. Thus, it is possible that the pD211N mutation
within DNAJC7 may conserve the structure but renders the phosphorylation site at pS207
inaccessible or more accessible to the kinase, which may prevent DNAJC7 from utilizing
its TPR domain to interact with Hsp90. Furthermore, the DNAJC7 mutation pE425K is
located within the flanking region of pK422 ubiquitination site of the J-domain. Multiple
studies have shown that the mutation of a ubiquitination site affects protein degradation
(Radivojac et al., 2010). However, at this time nothing is known about the effects of
mutations within the flanking regions of the ubiquitination site itself. It may be possible
that the location of pE425K within the flanking region of the ubiquitination site (pK422)
may affect the protein degradation of DNAJC7 in ALS patients.
Conversely, the pD8H mutation was found to be conserved based on the
properties of the amino acids (Figure 24). However, SIFT was not able to predict whether
pD8H would be tolerated or deleterious because the algorithm could not find any closely
related homologous sequences for this particular region (Figure 24). It is important to
note that this particular mutation would not be found in one of the two DNAJC7 isoforms
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within the cell. The second isoform of DNAJC7 does not contain the first 56 amino acids
(Uniprot ID Q99615-2). Thus, while pD8H can affect the function of the first isoform it
will not affect the function of the second isoform.

4.3.2 DNAJC7 Missense Mutations in Yeast
We cloned each of the following ALS-associated mutations pR412W and
pE425K, into human DNAJC7 and transformed each of these plasmids into yeast. Our
results show that all three of these stop mutations and their YFP-fused counterparts do
not make DNAJC7 toxic to the cell (Figure 25B, C). However, the untagged versions of
the mutated DNAJC7 protein are not present at levels comparable to wild-type DNAJC7
in yeast according to our western blot results (Figure 25D). This result could indicate
either that the mRNA is not expressed, or the mutant proteins undergo proteasomal
degradation or autophagy. Thus, the next steps would be to perform a qPCR in order to
determine if the gene is being expressed. If the gene is expressed, we can test whether the
inhibition of protein degradation stabilizes the mutants DNAJC7 proteins by using either
MG-132 (proteasome inhibitor) or BaffilomycinA1 (autophagy inhibitor).
The YFP-fused versions of DNAJC7 pR412W and pE425K show similar steadystate protein levels as wild-type DNAJC7 according to our western blots (Figure 25D)
and fluorescence microscopy (Figure 25F). The microscopy results indicate that DNAJC7
pR412W and pE425K do not mislocalize from the cytosol or form toxic aggregates.
However, it is possible that the YFP is speeding up the protein folding process(Dave et
al., 2016), thus stabilizing the mutated versions of DNAJC7 and preventing degradation.

4.3.3 DNAJC7 Nonsense Mutations in Yeast
According to a recent study, DNAJC7 in ALS individuals is associated with four
truncation variants (protein change: pE33X, pQ120X, pR156X, and pR216X)(Farhan et
al., 2019). Thus, we genetically engineered the following three DNAJC7 truncation
variants, pE33X, pQ120X, and pR216X (Figure 26A) and transformed them into yeast.
We also genetically engineered a DNAJC7 truncation construct solely to remove the
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functional J-domain of DNAJC7, pK380X (Figure 26A). Our results show that all four of
these nonsense mutations do not make DNAJC7 toxic to the cell (Figure 26B-C).
Furthermore, the fluorescent microscopy results indicate that the localization remained
diffused throughout the cytosol in all four truncation variants and that the proteins are not
degraded within the cell (Figure 26D). However, as discussed above for the missenses
mutations, it is possible that the YFP stabilizes the truncation variants and prevents their
degradation (Dave et al., 2016).

4.4 Conclusion
The results presented in this study confirm that DNAJC7 is a cytosolic chaperone
protein that interacts with both the Hsp70 and Hsp90 systems (Figure 31B). Furthermore,
we have established DNAJC7 as a novel chaperone protein that can reduce the toxicity of
ALS-associated proteins, TDP-43 and FUS. We propose that DNAJC7 allows TDP-43
and FUS to be passed from Hsp90 to Hsp70 to prevent toxic misfolding and toxic
interactions (Figure 31C). We have also shown that ALS-associated DNAJC7 missense
and nonsense mutations are not toxic to yeast, however, they may be degraded by the
cell. Thus, highlighting that one potential cause of ALS is the loss of function of
DNAJC7.
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Figure 31. Proposed mechanisms for the interaction between DNAJC7, Hsp90,
Hsp70, and ALS-associated proteins TDP-43 and FUS. A Under normal conditions
TDP-43 and FUS localize to the nucleus. DNAJC7, Hsp90, Hsp70 localize to the
cytoplasm. B In ALS, TDP-43 and FUS misfold, mislocalize, and aggregate within the
cytoplasm. Misfolded TDP-43 and FUS likely interact with Hsp90, Hsp70, and DNAJC7
to be either 1. folded properly or 2. to be tagged for proteasomal degradation. C Proposed
mechanism for the proper folding of TDP-43 or FUS through the bridging of Hsp90 and
Hsp70 by DNAJC7. 1. Misfolded TDP-43 or FUS bind to an Hsp40 which presents them
to Hsp70. 2. Sti1 bridges Hsp70 and Hsp90. Misfolded TDP-43 or FUS protein is passed
from Hsp70 to Hsp90. 3. DNAJC7 binds to Hsp90. 4. DNAJC7 bridges Hsp90 and
Hsp70 and allows TDP-43 or FUS to be passed to the Hsp70 for another folding cycle. 5.
Hsp70 completes the proper folding of TDP-43 or FUS and the NLS sequence on these
proteins allows them to localize to the nucleus.
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4.5 Limitations
4.5.1 Model Organisms
The yeast model is a powerful model organism to study the basic mechanisms of
protein quality control within the cell in the context of neurodegenerative diseases
(Tenreiro and Outeiro, 2010). However, the yeast model has its limitations. Yeast is a
unicellular organism, and do not contain differentiated cell types, such as motor neurons,
which are affected in neurodegenerative diseases. Thus, the yeast model cannot
recapitulate the cell-cell interactions seen in more sophisticated organisms. Furthermore,
yeast lack the complex pre-mRNA splicing machinery and alternative splicing methods
which are essential to eukaryotic gene expression. This is particularly important for this
study because there are two distinct isoforms of DNAJC7 in humans caused by
alternative splicing within the cell, however, for the purpose of this study we chose the
most common isoform of DNAJC7 to transform into the yeast model. Finally, yeast do
not produce endogenous DNAJC7, thus we used human DNAJC7 and expressed it in
yeast. This creates a potential limitation because yeast molecular chaperones normally do
not interact with DNAJC7. One route around this limitation is to engineer yeast to
possess entirely human chaperone pathways (Humanized yeast model) (Laurent et al.,
2016).
Some of our key findings in the yeast model were replicated and further explored
in a mammalian cell system, with a specific emphasize on mouse N2a cells and human
SH-SY5Y cells. The use of neuronal cell lines has greatly advanced our understanding of
protein misfolding and protein quality control in neurodegenerative diseases. It is,
however, important to note that these cell lines have limitations. Primary neuron cells
(motor neurons) have a finite lifespan, limited expansion capacity and are classified as
extremely sensitive and difficult to transfect. In comparison, neuronal cell lines (such as
N2a and SH-SY5Y) undergo cell division and proliferation which introduces the unique
problem of selective pressures resulting in genetic drift (Hughes et al., 2007). Thus,
neuronal cell lines may exhibit reduced or altered functions alongside different gene
expression patterns unlike neuronal cells in the CNS. In order to apply our study to ALS
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pathology further studies will have to be conducted in human neuronal cell lines (SHSY5Y cells), primary neurons, or induced pluripotent stem cells (iPS cells) from ALS
patients.
Finally, lumbar spinal cord sporadic ALS (sALS) patient samples were also
utilized in this study to support our yeast and mammalian cell culture work. The
limitation of these samples is that we did not know their genetic makeup. It is unlikely
that any of these sALS patient samples have a DNAJC7 mutation as DNAJC7 mutations
are only present in 0.2% of all ALS cases(Farhan et al., 2019). Thus, our
immunohistochemical study may not represent the true localization of DNAJC7 in an
ALS patient with DNAJC7 mutations. Furthermore, we analysed the endogenous protein
levels in sALS samples, which may not accurately represent DNAJC7 levels in patients
with DNAJC7 mutations.

4.5.2 ∆Sti1 Growth Phenotype
As described in the results section the ∆Sti1 yeast strain did not display any
growth phenotype making it difficult to determine if the addition of DNAJC7 is able to
compensate for the deletion (Figure 21A, B, C, D). However, the literature suggests that
DNAJC7 is unable to compensate for the siRNA knockdown of Hop (Sti1 human
homolog) in HeLa cells (Cintrón Moffatt et al., 2008). We thus need to expand our
studies into mammalian cells with reduced expression and function of Sti1.

4.5.3 DAmP Yeast Strain
DAmP yeast strains are useful genetic tools to analyze the role of essential genes
within the yeast model. For the purposes of this study we used a DAmP strain of Cdc37,
which is an essential Hsp90 co-chaperone protein. DAmP allele libraries are created by
replacing the 3’ noncoding regions with non-functional sequences that destabilize the
mRNA, thus reducing the mRNA abundance within the yeast cell. However, the growth
defect caused by the DAmP allele can be suppressed by a spontaneous mutation in the
genes NMD2 and NAM7, which can stabilize the mRNA and increase the transcription
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and translation of the mRNA (van Leeuwen et al., 2017). In order to mitigate this affect
we preformed our experiments with smaller yeast colonies which are less likely to
contain the suppressor mutations.

4.5.4 COVID-19
Unfortunately, the world is in the process of navigating the COVID-19 pandemic
which initially led to the closure of Western University starting in March 2020 and then
eventually strict on-going limitations beginning July 2020. Due to these constraints parts
of this project were re-organized and removed. For instance, we initially planned on
determining whether the ALS-associated DNAJC7 mutation constructs prevented
DNAJC7 from rescuing TDP-43 and FUS toxicity. However, we were only able to
engineer the constructs without conducting experiments with them due to the pandemic
time restrictions. Furthermore, our cell culture data was to be performed and optimized in
both N2a and SH-SY5Y cells to avoid cell-lineage specific effects. However, we were
only able to begin the work in N2a cells without verifying our results in SH-SY5Y cells.
The drug (Radicicol, AZC, H2O2) concentrations and time treatment intervals were in the
process of being optimized as well as the siRNA knockdown protein concentrations. For
example, the 1mM H2O2 treatment for 16 hours needed to be decreased both in
concentration and time. H2O2 should only be introduced for approximately 3-4 hours to
avoid complete cell death. Finally, the human spinal cord tissue western blot protocol
was in the process of being optimized to avoid unspecific bands.

4.6 Future Work
The ability of DNAJC7 to rescue TDP-43/FUS toxicity, except in the absence of
the Hsp90 system, is an exciting novel finding that has great potential to provide us with
insight into the mechanism that is responsible for folding these ALS-associated proteins.
However, several questions remain unanswered regarding the mechanism by which
DNAJC7 reduces TDP-43/FUS toxicity: first, it is unclear whether DNAJC7 is directly
interacting with TDP-43/FUS. To study this, we would perform a co-localization
microscopy as well as a co-immunoprecipitation in both yeast and mammalian cells.

88
Furthermore, we can verify the strength of the physical interaction using surface plasmon
resonance with purified DNAJC7; second, it is be unclear whether DNAJC7 is
responsible for folding or degrading TDP-43/FUS. To address this, we would inhibit
protein degradation through proteasome (MG-132) and autophagy (Baffilomycin A1) and
determine whether DNAJC7 can still rescue the toxicity of TDP-43/FUS and the protein
levels of TDP-43/FUS; third, if DNAJC7 is confirmed to be part of the folding process
for TDP-43/FUS we would need to elucidate the folding mechanism. To study this, we
could purify the proteins involved (Hsp70, Hsp90, DNAJC7, TDP-43, and FUS) and
TDP-43/FUS. This would allow us to monitor the transfer of TDP-43/FUS from one
chaperone to another in a defined in vitro system.
We successfully cloned ALS-associated DNAJC7 missense and nonsense
mutations, however whether these mutations affect DNAJC7 function in reducing TDP43/FUS toxicity is still unknown. Thus, if DNAJC7 is responsible for folding TDP43/FUS we can repeat some of the experiments listed above with the missense and
nonsense mutations. It would be important to translate these results into mammalian cells,
which would involve creating stable constructs of the mutations, e.g. using expression via
lentivirus. We can then conduct experiments knocking out endogenous DNAJC7 using
CRISPR-Cas9 and monitor cell viability as well as aggregation of TDP-43/FUS.
For the DNAJC7 nonsense mutations, it is unclear whether these mutations lead
to non-sense mediated decay (NMD), degradation of the protein, or the accumulation of
the nonsense DNAJC7 proteins. Interestingly, Farhan et al, discovered that in ALS
patients possessing one of the nonsense mutations in DNAJC7 (pR156x) the mRNA
levels were unaffected, however the protein was not detected(Farhan et al., 2019). Thus,
it would be important to study the fate of the nonsense mutated DNAJC7 mRNA and
protein. To study this, we would express the full gene (pre-mRNA) of each of the
DNAJC7 nonsense mutations and monitor the RNA levels with qPCR, protein levels, and
cell viability with and without the inhibition of NMD-pathway.
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4.7 Significance
This study investigated DNAJC7 as a molecular chaperone involved in protein
misfolding in ALS. Due to the recent discovery of DNAJC7 mutations associated with
ALS, very little is known about its mechanistic function in protein quality control in
ALS. Here, we successfully established a yeast model to investigate DNAJC7 function.
Our results confirm the previous observation that DNAJC7 interactions with Hsp70 and
Hsp90. Furthermore, our results signify that DNAJC7 is able to reduce TDP-43/FUS
toxicity, but not in the absence of Hsp90 chaperones. This is a novel finding that
encourages further mechanistic and pathological studies. Further studies may be able to
establish whether DNAJC7 is responsible for folding or degrading TDP-43/FUS, and
how DNAJC7 uses the Hsp70/90 system to perform these functions. This might lead to a
better understanding of how dysfunction of molecular chaperones, specifically DNAJC7,
and protein misfolding contributes to ALS and other neurodegenerative diseases.

4.8 Clinical Implications
This project indicates that DNAJC7 may play a protective role in properly
folding, refolding or degrading misfolded proteins TDP-43 and FUS in individuals with
ALS. Thus, it might be of clinical relevance to design a drug that mimics the role of
DNAJC7 in folding, re-folding or degrading TDP-43 and FUS to reduce their
proteinopathy in ALS patients.
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Appendices
Appendix A: Supplementary Figures
A

B

Figure 31. Yeast cells cannot grow when treated with 1mM or 2mM of AZC.
Growth assays of yeast cells expressing DNAJC7 grown on media containing 1mM or
2mM of AZC at 30°C. YPD plates are shown as a control.

A

B

Figure 32. Complete western blots for figure 25D.
A Western blot showing DNAJC7 protein expression levels in yeast cells expressing
either DNAJC7, pR412W, or pE425K. B Western blot showing PGK-1 control protein
levels (the same samples as A) in yeast cells expressing either DNAJC7, pR412W, or
pE425K. L indicates the location of the ladder, and # indicates an empty well.
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A

B

C

Figure 33. Complete western blots for figure 35E.
A Western blot showing expression levels in yeast cells expressing either DNAJC7-YFP,
pR412W-YFP, or pE425K-YFP. (Anti-GFP antibody recognizes YFP). No signal
detected. B ECL detection used for the same western blot in A. The ladder was not
compatible with ECL therefore it cannot be detected in this image. C Western blot
showing the protein expression levels of PGK-1 control in yeast cells expressing
DNAJC7-YFP, pR412W-YFP, or pE425K-YFP. L indicates the location of the ladder,
and # indicates an empty well.
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A

B

Figure 34. Complete western blots for figure 27A.
A Western blot showing endogenous DNAJC7 levels in N2a and SH-S5Y5 cells. B
Western blot of PGK-1 in N2a and SH-S5Y5 cells (the same samples as A). L indicates
the location of the ladder, * indicates ladder spill into an empty well, and # indicates an
empty well.
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B
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Figure 35. Complete western blots for figure 28A. A Western blot showing siRNA
knock down of DNAJC7 in N2a cells in comparison to scrambled control siRNA. A
DNAJC7 transformed yeast lysate and untreated N2a cell lysate were used as controls.
Probed with anti-DNAJC7 antibody. B Western blot probed with anti-PGK-1 control
antibody. L indicates the location of the ladder, * indicates ladder spill into empty well, #
indicates empty well with spill from DNAJC7 yeast lysate.
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Figure 36. Complete western blots for figure 28C. Red arrowhead indicate the bands
shown in figure 28C.
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Figure 37. Complete set of three n for figure 29B. Immunohistochemistry images of
the human spinal cord from neurologically normal and sALS patients stained for
DNAJC7 (1:500). Black arrow heads locate motor neurons. Red arrow heads indicate the
images used in figure 29B.
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A

B
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Figure 38. Complete western blots for figure 30A and B. A Sedimentation assay of
Endogenous DNAJC7 (57 kDa) levels in unaffected (control) and sALS patient spinal
cord tissue. B Endogenous DNAJA1 (45 kDa) levels in unaffected (control) and sALS
patient spinal cord tissue. L indicates the location of the ladder, # indicates an empty
well, read arrow heads indicate the bands shown in figure 30A and B.
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